Compositions and methods for treating PCDH19 related conditions
By targeting PCDH19 mutations using single-stranded oligonucleotides that are highly complementary to the PCDH19 gene, the problem of lack of effective treatment of PCDH19-related diseases in the prior art is solved, and significant reduction and prevention of symptoms of these diseases is achieved.
Patent Information
- Application Number
- CN202280075503.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-22
- Filing Date
- 2022-09-27
- Publication Date
- 2024-11-08
AI Technical Summary
There is a lack of effective treatments in the prior art to deal with PCDH19-related diseases, such as epilepsy, schizophrenia and autism, especially neurological diseases caused by mutations in the PCDH19 gene.
A single-stranded oligonucleotide compound containing a target region of the human PCDH19 gene, its precursor mRNA transcript or mRNA transcript was developed for targeting PCDH19 mutations by using mutation-containing mRNA or precursor mRNA Selective hybridization, thereby reducing the expression and activity of the PCDH19 gene.
By reducing the expression and activity of the PCDH19 gene, significantly alleviating or preventing the symptoms of PCDH19-related diseases, a novel approach to treating these diseases is provided.
Smart Images

Figure GDA0004934683980000181 
Figure GDA0004934683980000191 
Figure GDA0004934683980000201
Abstract
Description
[0001] Related Applications
[0002] This application claims priority to U.S. Provisional Application No. 63 / 248,803, filed on September 27, 2021, entitled “Compositions and Methods for Treating PCDH19-Related Disorders,” and U.S. Provisional Application No. 63 / 333,840, filed on April 22, 2022, entitled “Compositions and Methods for Treating PCDH19-Related Disorders,” the entire contents of which are hereby incorporated by reference in their entirety. Technical Field
[0003] The present invention relates to antisense oligonucleotides complementary to the target region of the human PCDH19 gene, its pre-mRNA transcript and / or its mRNA transcript. Embodiments of the present invention also relate to compositions and methods for treating, reducing at least one symptom or preventing PCDH19-related disorders (such as epilepsy, schizophrenia or autism). Background Art
[0004] Protocadherin 19 (PCDH19) is a cell surface protein expressed in neurons that may play a role in cell-cell adhesion. Mutations in the PCDH19 gene are associated with neurological disorders such as epilepsy, autism, and schizophrenia. Interestingly, PCDH19-related early infantile epileptic encephalopathy type 9 (EIEE9) is an X-linked disorder in which heterozygous females are affected but hemizygous males are not affected. Although rare, mutations in PCDH19 can also affect mosaic male carriers. Although people with PCDH19 mutations can be diagnosed through genetic screening, there are currently no known treatments for PCDH19-related disorders such as epilepsy. Therefore, new compositions and methods for treating these diseases are needed. Summary of the invention
[0005] In one aspect, the present invention provides a compound comprising a single-stranded oligonucleotide having a length of 10-80 nucleotides and a nucleobase sequence comprising a portion of 10 consecutive nucleobases, which has at least 80% (e.g., 85%, 90%, 95%, 97%, 99% or 100%) complementarity to an equal length portion of a target region of a human PCDH19 gene, its pre-mRNA transcript and / or its mRNA transcript.
[0006] In specific embodiments, the target region is within the nucleotide sequence set forth in SEQ ID NO: 1 or a variant thereof having at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity. In specific embodiments, the single-stranded oligonucleotide hybridizes to a PCDH19 pre-mRNA transcript or an mRNA transcript.
[0007] In some embodiments, the mRNA transcript or pre-mRNA transcript may include at least one PCDH19 mutation. The mutation may be, for example, a mutation encoding N340S, E307K, V441E, Q85X, N557K, D594H, S671X, L677fsx717, I119fsX122, and P364fsX375. The mutation may be a mutation selected from Table 1. The oligonucleotide may selectively hybridize with an mRNA transcript or pre-mRNA transcript comprising at least one PCDH19 mutation, but not with a wild-type mRNA transcript or pre-mRNA transcript. Therefore, the oligonucleotide may be an allele-specific oligonucleotide.
[0008] In some embodiments, an oligonucleotide consists of 12 to 40 (eg, 15 to 30, such as 16 to 22, such as 15, 16, 17, 18, 19, 20, 21 or 22) nucleobases.
[0009] In some embodiments, the oligonucleotide comprises: a gap segment comprising linked deoxyribonucleosides; a 5' wing segment comprising linked nucleosides; and a 3' wing segment comprising linked nucleosides. The gap segment may comprise a region of at least 10 consecutive nucleobases, which has at least 80% (e.g., 85%, 90%, 95%, 97%, 99% or 100%) complementarity to a portion of the target region of a precursor mRNA transcript or mRNA transcript of a human PCDH19 gene, and is located between the 5' wing segment and the 3' wing segment. The 5' wing segment and the 3' wing segment each comprise at least two linked nucleosides, and at least one nucleoside of each wing segment comprises an alternative nucleoside.
[0010] In some embodiments, the oligonucleotide comprises at least one alternative internucleoside bond. The at least one alternative internucleoside bond can be a thiophosphate internucleoside bond. The at least one alternative internucleoside bond can be a 2'-alkoxy internucleoside bond. The at least one alternative internucleoside bond can be an alkyl phosphate internucleoside bond.
[0011] In some embodiments, the oligonucleotide comprises at least one alternative nucleobase. The alternative nucleobase may be 5'-methylcytosine, pseudouridine or 5-methoxyuridine.
[0012] In some embodiments, the oligonucleotide comprises at least one alternative sugar moiety. The alternative sugar moiety may be a 2'-OMe modified sugar moiety or a bicyclic sugar moiety.
[0013] In some embodiments, the oligonucleotide further comprises a ligand conjugated to the 5' end or the 3' end of the oligonucleotide via a monovalent or branched bivalent or trivalent linker.
[0014] In some embodiments, the oligonucleotide comprises a region of complementarity to at least 15 (eg, 15, 16, 17, 18, 19, 20, or 21) consecutive nucleotides of a PCDH19 gene.
[0015] In some embodiments, the oligonucleotide comprises the sequence set forth in any one of SEQ ID NOs: 2-385.
[0016] In another aspect, the present invention provides a pharmaceutical composition comprising the oligonucleotide according to any one of the above embodiments and a pharmaceutically acceptable carrier or excipient.
[0017] In another aspect, the present invention provides a composition comprising the oligonucleotide of any one of the above embodiments and a lipid nanoparticle, a polyplex nanoparticle, a lipoplex nanoparticle or a liposome.
[0018] On the other hand, the present invention provides a method for treating, preventing or delaying the progression of a PCDH19-related disease in a subject in need thereof, which is performed by administering to the subject an oligonucleotide, pharmaceutical composition or composition according to any one of the above embodiments, and the amount and duration of administration are sufficient to treat, prevent or delay the progression of the PCDH19-related disease.
[0019] Also provided herein is the use of the oligonucleotide of the present invention in the manufacture of a medicament for treating, preventing or delaying the progression of a PCDH19-related disease.
[0020] On the other hand, the present invention provides a method for inhibiting PCDH19 transcription in cells of a subject suffering from a PCDH19-related disease, which is performed by contacting the cells with the oligonucleotide, pharmaceutical composition or composition of any one of the above embodiments, and the amount and duration of contact are sufficient to obtain degradation of the mRNA transcript of the PCDH19 gene, so that the oligonucleotide inhibits the expression of the PCDH19 gene in the cell.
[0021] The cells can be contacted in vivo or ex vivo.
[0022] In another aspect, the present invention provides a method for reducing the level and / or activity of PCDH19 in cells of a subject suffering from a PCDH19-related disorder, by contacting the cells with an oligonucleotide, pharmaceutical composition or composition of any one of the above embodiments, the amount and duration of contact being sufficient to reduce the level and / or activity of PCDH19 in the cells.
[0023] The cells can be contacted in vivo or ex vivo.
[0024] In some embodiments of the above aspects, the subject is a human. The subject may be male. The subject may be female.
[0025] In some embodiments of the above aspects, the cell is a cell of the central nervous system.
[0026] In some embodiments of the above aspects, the PCDH19-related disorder is selected from epilepsy, schizophrenia, and autism.
[0027] In some embodiments of the above aspects, the PCDH19-related disorder is epilepsy. The epilepsy can be epileptic early infantile encephalopathy type 9.
[0028] In some embodiments of the above aspects, the subject has a mutation in at least one allele of the PCDH19 gene. The mutation can be heterozygous (e.g., if the subject is a woman). The mutation can be hemizygous (e.g., if the subject is a man). If the subject is a man, the subject can have a mosaic mutation, wherein a portion of the cells contain the mutation. The mutation can be a missense mutation or a nonsense mutation. The mutation can be a frameshift mutation. The mutation can be an insertion or a deletion.
[0029] In some embodiments of the above aspects, the oligonucleotide selectively reduces expression of an allele comprising the mutation relative to an allele that does not comprise the mutation.
[0030] In some embodiments of the above aspects, the oligonucleotide reduces expression of both the allele comprising the mutation and the allele comprising the wild-type sequence.
[0031] In some embodiments of the above aspects, the treatment reduces one or more symptoms of a PCDH19-related disorder. The one or more symptoms of a PCDH19-related disorder can be selected from the group consisting of long-term epileptic seizures, frequent epileptic seizures, behavioral and developmental delays, movement and balance problems, orthopedic conditions, language and speech delay problems, growth and nutrition problems, sleep difficulties, chronic infections, sensory integration disorders, autonomic nervous system disorders, and sweating. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] Exemplary embodiments of the present disclosure are herein described, by way of non-limiting example only, with reference to the following drawings.
[0033] Figure 1 .Relative expression of PCDH19 mRNA in HEK293 cells 48 h after transfection with 0.2 nM (grey bars) and 2.0 nM (black bars) of exemplary antisense oligonucleotides (ASOs). Data for PCDH19 mRNA were normalized with GAPDH mRNA and expressed as the combined mean of cells transfected with mock-transfected cells and Ahsa1 ASOs that do not cross-react with PCDH19. Data are shown as the mean and standard deviation calculated from n=4 independent experiments. The ASO number (abscissa value) corresponds to the ASO number shown in Table 2.
[0034] SEQ ID NO: 1 describes the nucleotide sequence of the human PCDH19 gene of NCBI reference sequence NC_000023.11 (region 100291644..100410273). Exemplary ASOs of the invention are shown in SEQ ID NO: 2-385 (Table 2).
[0035] definition
[0036] For convenience, the meanings of some terms and phrases used in the specification, examples, and appended claims are provided below. Unless otherwise specified or implied by the context, the following terms and phrases include the meanings provided below. These definitions are provided to help describe specific embodiments and are not intended to limit the claimed technology, as the scope of the technology is limited only by the claims. Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those generally understood by those of ordinary skill in the art to which the technology belongs. If there is a significant difference between the use of a term in the art and the definition provided herein, the definition provided in the specification shall prevail.
[0037] In this application, unless the context clearly indicates otherwise, (i) the term "a" or "an" may be understood to mean "at least one"; (ii) the term "or" may be understood to mean "and / or"; and (iii) the terms "including" and "comprising" may be understood to cover the components or steps listed itemized, whether listed alone or together with one or more additional components or steps.
[0038] As used herein, the terms "about" and "approximately" refer to values within 10% above or below the described value. For example, the term "about 5 nM" means a range of 4.5 to 5.5 nM.
[0039] As is clear from the context, the term "at least" before a number or a series of numbers is understood to include the number adjacent to the term "at least", as well as all subsequent numbers or integers that may be logically included. For example, the number of nucleotides in a nucleic acid molecule must be an integer. For example, "at least 18 nucleotides in a nucleic acid molecule of 21 nucleotides" means that 18, 19, 20 or 21 nucleotides have the indicated properties. When "at least" is present before a series or range of numbers, it is understood that "at least" can modify each number in the series or range.
[0040] As used herein, "not more than" or "less than" is understood to mean the value adjacent to the phrase and the logical lower value or integer, to zero, as is logical from the context. For example, an oligonucleotide with "not more than 3 mismatches with the target sequence" has 3, 2, 1, or 0 mismatches with the target sequence. When "not more than" precedes a numerical series or range, it is understood that "not more than" can modify each number in the series or range.
[0041] Throughout this specification and the appended claims, unless the context requires otherwise, the word "comprise" and variations such as "comprises" and "comprising" will be understood to mean the inclusion of a stated integer or step, or group of integers or steps, but not the exclusion of any other integer or step, or group of integers or steps.
[0042] As used herein, the term "administering" refers to administering a composition (e.g., a compound or formulation comprising a compound as described herein) to a subject or system. Administration to an animal subject (e.g., to a human) can be by any appropriate route (e.g., a route as described herein).
[0043] As used herein, "combination therapy" or "combination administration" refers to the administration of two (or more) different agents or treatments to a subject as part of a determined treatment regimen for a specific disease or condition. The treatment regimen defines the dosage and administration cycle of each agent so that the effects of individual agents on the subject overlap. In some embodiments, the delivery of two or more agents is simultaneous or concurrent, and the agents can be co-formulated. In some embodiments, two or more agents are not co-formulated and are administered in a sequential manner as part of a prescription regimen. In some embodiments, two or more agents or treatments are administered in combination so that the reduction in symptoms or other parameters associated with the illness is greater than the reduction observed when a single agent or treatment is delivered or there is no other drug or treatment. The effects of the two treatments can be partially cumulative, completely cumulative, or greater than cumulative (e.g., synergistic). Each therapeutic agent can be administered sequentially or substantially simultaneously by any appropriate route, including but not limited to oral routes, intravenous routes, intramuscular routes, and direct absorption by mucosal tissues. Therapeutic agents can be administered by the same route or by different routes. For example, a first therapeutic agent of the combination may be administered intravenously, while a second therapeutic agent of the combination may be administered orally.
[0044] As used herein, the terms "PCDH19" and "protocadherin 19" refer to a calcium-dependent cell adhesion protein that is primarily expressed in the developing brain. Unless otherwise indicated, PCDH19 may have an amino acid sequence from any vertebrate or mammalian source, including but not limited to humans, cattle, chickens, rodents, mice, rats, pigs, sheep, primates, monkeys, and guinea pigs. The term also refers to fragments and variants of natural PCDH19 that retain at least one in vivo or in vitro activity of natural PCDH19. The term encompasses the full-length unprocessed precursor form of PCDH19 and the mature form produced by post-translational cleavage of the signal peptide. PCDH19 is encoded by the PCDH19 gene. The nucleic acid sequences of exemplary human PCDH19 genes are listed in NCBI reference numbers NC_000023.11, NG_021319.1, NM_001105243.1, NM_001184880.1, and NM_020766.2. The term "PCDH19" also refers to natural variants of wild-type PCDH19 proteins, such as proteins that have at least 85% identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9% identity or more) to the amino acid sequence of wild-type human PCDH19.
[0045] As used herein, the term "PCDH19" also refers to a specific polypeptide expressed in a cell by a naturally occurring DNA sequence variation of the PCDH19 gene (such as a single nucleotide polymorphism in the PCDH19 gene). Many SNPs within the PCDH19 gene have been identified and can be found, for example, in NCBI dbSNP (see, for example, www.ncbi.nlm.nih.gov / snp).
[0046] As used herein, "target sequence" refers to a continuous portion of the nucleotide sequence of an mRNA molecule (including mRNA as a product of RNA processing of a primary transcription product) formed during the transcription of a PCDH19 gene. In one embodiment, the target portion of the sequence will be at least long enough to serve as a substrate for oligonucleotide-directed (e.g., antisense oligonucleotide (ASO)-directed) cutting, which is performed at or near the portion of the nucleotide sequence of the mRNA molecule formed during the transcription of the PCDH19 gene. The target sequence can be, for example, about 9-36 nucleotides in length, such as about 15-30 nucleotides in length, such as about 18-22 nucleotides in length. For example, the target sequence can be about 15-30 nucleotides, 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-2 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23 or 21-22 nucleotides. Ranges and lengths between the above ranges and lengths are also considered part of the invention.
[0047] "G", "C", "A", "T" and "U" each generally represent a naturally occurring nucleotide containing guanine, cytosine, adenine, thymidine and uracil as bases, respectively. However, it will be understood that, as further described in detail below, the term "nucleotide" may also refer to an alternative nucleotide, or an alternative replacement portion. It is well known to the skilled person that guanine, cytosine, adenine and uracil can be replaced by other parts without substantially changing the base pairing properties of the oligonucleotide containing the nucleotide with such replacement part. For example, but not limited to, a nucleotide containing inosine as a base can be base paired with a nucleotide containing adenine, cytosine or uracil. Therefore, in the nucleotide sequence of the oligonucleotides to which the present invention is particularly directed, a nucleotide containing uracil, guanine or adenine can be replaced by a nucleotide containing, for example, inosine. In another example, adenine and cytosine at any position in the oligonucleotide can be replaced with guanine and uracil, respectively, to form a GU wobble base pairing with the target mRNA. Sequences containing such replacement moieties are suitable for use in particular contemplated compositions and methods of the invention.
[0048] The terms "nucleobase" and "base" include purines (e.g., adenine and guanine) and pyrimidines (e.g., uracil, thymine, and cytosine) present in nucleosides and nucleotides, which form hydrogen bonds in nucleic acid hybridization. In the context of the present invention, the term nucleobase also encompasses alternative nucleobases, which may be different from naturally occurring nucleobases, but work during nucleic acid hybridization. In this case, "nucleobase" refers to both naturally occurring nucleobases, such as adenine, guanine, cytosine, thymidine, uracil, xanthine, and hypoxanthine, and also to alternative nucleobases. Such variants are described, for example, in Hirao et al. (2012) Accounts of Chemical Research vol.45, p.2055 and Bergstrom (2009) Current Protocols in Nucleic Acid Chemistry Suppl.37 1.4.1.
[0049] The term "nucleoside" refers to a monomeric unit of an oligonucleotide or polynucleotide having a nucleobase and a sugar moiety. Nucleosides can include naturally occurring nucleosides as well as alternative nucleosides, such as those described herein. The nucleobase of a nucleoside can be a naturally occurring nucleobase or an alternative nucleobase. Similarly, the sugar moiety of a nucleoside can be a naturally occurring sugar or an alternative sugar.
[0050] The term "alternative nucleoside" refers to nucleosides with alternative sugars or alternative nucleobases, such as those described herein.
[0051] In some embodiments, the nucleobase moiety is modified by changing a purine or pyrimidine to a modified purine or pyrimidine, such as a substituted purine or substituted pyrimidine, such as an "alternative nucleobase" selected from the group consisting of isocytosine, pseudoisocytosine, 5-methylcytosine, 5-thiazolocytosine, 5-propynylcytosine, 5-propynyluridine, 5-bromouridine, 5-thiazolouridine, 2-thiouridine, pseudouridine, 1-methylpseudouridine, 5-methoxyuridine, 2′-thiothymine, inosine, diaminopurine, 6-aminopurine, 2-aminopurine, 2,6-diaminopurine, and 2-chloro-6-aminopurine.
[0052] The nucleobase moiety may be represented by the letter code for each corresponding nucleobase, such as A, T, G, C or U, wherein each letter may optionally include an alternative nucleobase having an equivalent function. In some embodiments, such as for gapmers, 5-methylcytosine LNA nucleosides may be used.
[0053] "Sugar" or "sugar moiety" includes naturally occurring sugars having a furanose ring. Sugars also include "alternative sugars", which are defined as structures that can replace the furanose ring of a nucleoside. In certain embodiments, the alternative sugar is a non-furanose (or 4'-substituted furanose) ring or ring system or open system. Such structures include simple changes relative to the natural furanose ring, such as a six-membered ring, or can be more complex, such as the case of a non-ring system used in peptide nucleic acids. Alternative sugars can also include sugar substitutes in which the furanose ring has been replaced with another ring system (e.g., a morpholino or hexitol ring system). Sugar moieties that can be used to prepare oligonucleotides having motifs include, but are not limited to: β-D-ribose, β-D-2'-deoxyribose, substituted sugars (such as 2', 5' and disubstituted sugars), 4'-S-sugars (such as 4'-S-ribose, 4'-S-2'-deoxyribose and 4'-S-2'-substituted ribose), bicyclic alternative sugars (such as 2'-O—CH 2 -4′ or 2′-O—(CH 2 ) 2 -4' bridged ribose derived bicyclic sugars) and sugar surrogates (such as when the ribose ring has been replaced with a morpholinyl or hexitol ring system). The type of heterocyclic base and internucleoside bond used at each position is variable and is not a factor in determining the motif. In most nucleosides with alternative sugar moieties, the heterocyclic nucleobase is generally maintained to allow hybridization.
[0054] As used herein, "nucleotide" refers to the monomeric unit of an oligonucleotide or polynucleotide, which includes a nucleoside and an internucleoside bond. The internucleoside bond may include or may not include a phosphate bond. Similarly, "connected nucleosides" may be connected by or without a phosphate bond. Many "alternative internucleoside bonds" known in the art include, but are not limited to, phosphate bonds, phosphorothioate bonds, and borophosphate bonds. Alternative nucleosides include other variants of the phosphate backbone of bicyclic nucleosides (BNA) (e.g., locked nucleosides (LNA) and constrained ethyl (cEt) nucleosides), peptide nucleosides (PNA), phosphotriesters, phosphorothioates, phosphoramidates, and natural nucleosides, including those described herein.
[0055] As used herein, "alternative nucleotide" refers to a nucleotide having alternative nucleosides or alternative sugars and internucleoside linkages (which may include alternative nucleoside linkages).
[0056] As used herein, as generally understood by the skilled artisan, the terms "oligonucleotide" and "polynucleotide" are defined as molecules comprising two or more covalently linked nucleosides. Such covalently linked nucleosides may also be referred to as nucleic acid molecules or oligomers. The term "oligonucleotide" refers to short polynucleotides (usually 100 or less connected nucleosides). Oligonucleotides are usually prepared in the laboratory by solid phase chemical synthesis followed by purification. When referring to the sequence of an oligonucleotide, the sequence or order of the core base portion of the covalently linked nucleotides or nucleosides or their modification is then referred to. The oligonucleotide of the present invention can be artificial, chemically synthesized, and usually purified or separated. Oligonucleotides are also intended to include (i) compounds with one or more furanose moieties, the furanose moieties being replaced by furanose derivatives or any structure (cyclic or acyclic) that can be used as a covalent attachment point for a base moiety, (ii) compounds with one or more phosphodiester bonds, the phosphodiester bonds being modified, such as in the case of a phosphoramidate bond or a phosphorothioate bond, or being completely replaced by a suitable linking portion, such as in the case of a methylal bond or a riboacetal bond, and / or (iii) compounds with one or more connected furanose-phosphodiester bond portions, the portions being replaced by any structure (cyclic or acyclic) that can be used as a covalent attachment point for a base moiety. The oligonucleotides of the present invention may comprise one or more alternative nucleosides or nucleotides (e.g., comprising those alternative nucleosides or nucleotides described herein). It is also understood that the oligonucleotides comprise components lacking sugar moieties or core bases, but are still capable of forming a pair or hybridization with a target sequence.
[0057] In the context of the present disclosure, the terms "compound" and "oligonucleotide" may be used interchangeably. However, falling within the scope of the term "compound" may be a compound that includes or comprises an oligonucleotide as disclosed herein, and further includes or comprises one or more additional moieties.
[0058] In the context of the present invention, a "chimeric" oligonucleotide or "chimera" is an oligonucleotide containing two or more chemically distinct regions, each region consisting of at least one monomer unit (ie, a nucleotide or nucleoside in the case of an oligonucleotide). Chimeric oligonucleotides also include "gapmers".
[0059] The oligonucleotides can be of any length that allows for specific degradation of the desired target RNA by an RNase H-mediated pathway, and can range in length from about 10-30 base pairs, such as about 15-30 base pairs in length or about 16-22 (e.g., 18-20) base pairs in length, such as about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75 22, 23, 24, 25, 26, 27, 28, 29 or 30 base pairs in length, such as about 15-30, 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 19-21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 base pairs in length, such as about 15-30, 15-29, 15-28, 15-27, 15-26, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 1 21-24, 21-23, 21-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23 or 21-22 base pairs. Ranges and lengths between the above ranges and lengths are also considered part of the invention.
[0060] As used herein, the term "oligonucleotide comprising a nucleobase sequence" refers to an oligonucleotide comprising a chain of nucleotides or nucleosides described by reference to the sequence using standard nucleotide nomenclature.
[0061] The term "continuous core base region" refers to an oligonucleotide region complementary to a target nucleic acid. The term can be used interchangeably with the term "continuous nucleotide sequence" or "continuous core base sequence" in this article. In some embodiments, all nucleotides of an oligonucleotide are present in a continuous nucleotide or nucleoside region. In some embodiments, an oligonucleotide comprises a continuous nucleotide region, and may optionally comprise further nucleotides or nucleosides, such as a nucleotide joint region, which may be used to connect a functional group to a continuous nucleotide sequence. The nucleotide joint region may be complementary or non-complementary to a target nucleic acid. In some embodiments, the internucleoside bonds between the nucleotides present in the continuous nucleotide region are all thiophosphate internucleoside bonds. In some embodiments, the continuous nucleotide region comprises one or more sugar-modified nucleosides.
[0062] As used herein, the term "gapmer" refers to an oligonucleotide comprising an oligonucleotide region (gap) for recruiting ribonuclease H, whose 5' and 3' flanks are regions (wings or flanks) comprising one or more alternative nucleosides that enhance affinity. Various gapmer designs are described herein. Headmers and tailmers are oligonucleotides that can recruit ribonuclease H when one of the wings is missing, i.e., only one of the ends of the oligonucleotide comprises an alternative nucleoside that enhances affinity. For headmers, 3' wings are lacking (i.e., 5' wings comprise alternative nucleosides that enhance affinity), while for tailmers, 5' wings are lacking (i.e., 3' wings comprise alternative nucleosides that enhance affinity). A "mixed-wing gapmer" refers to a gapmer in which the wing comprises at least one alternative nucleoside, such as at least one DNA nucleoside or at least one 2'-substituted alternative nucleoside, for example, 2'-O-alkyl-RNA, 2'-O-methyl-RNA, 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA (MOE), 2'-amino-DNA, 2'-fluoro-RNA, 2'-F-ANA nucleoside or a bicyclic nucleoside (e.g., a locked nucleoside or a constrained ethyl (cEt) nucleoside). In some embodiments, one wing of a mixed-wing gapmer comprises an alternative nucleoside (e.g., 5' or 3') and the other wing (3' or 5', respectively) comprises a 2'-substituted alternative nucleoside.
[0063] The term "joint" or "linking group" is a connection between two atoms, which connects a chemical group or a fragment of interest to another chemical group or a fragment of interest via one or more covalent bonds. The conjugated moiety can be directly connected to the oligonucleotide, or connected to the oligonucleotide by a connecting moiety (e.g., a joint or a tether). The joint is used to covalently connect the third region (e.g., conjugated moiety) to the oligonucleotide (e.g., the end of region A or C). In some embodiments of the invention, the conjugate or oligonucleotide conjugate of the present invention may optionally include a joint region between the oligonucleotide and the conjugate moiety. In some embodiments, the joint between the conjugate and the oligonucleotide is biodegradable. The phosphodiester containing a biodegradable joint is described in more detail in WO 2014 / 076195 (incorporated herein by reference).
[0064] As used herein, and unless otherwise indicated, as will be understood by the skilled artisan, the term "complementary" when used to describe a first nucleotide or nucleoside sequence relative to a second nucleotide or nucleoside sequence refers to the ability of an oligonucleotide or polynucleotide comprising a first nucleotide or nucleoside sequence to hybridize and form a duplex structure with an oligonucleotide or polynucleotide comprising a second nucleotide sequence under certain conditions. Such conditions may, for example, be stringent conditions, wherein stringent conditions may include: 400 mM NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA, 50°C or 70°C for 12-16 hours, followed by washing (see, e.g., Molecular Cloning: A Laboratory Manual, Sambrook et al. (1989) Cold Spring Harbor Laboratory Press). Other conditions, such as physiologically relevant conditions that may be encountered in vivo, may also be applicable. The skilled artisan will be able to determine the set of conditions that are most suitable for testing the complementarity of two sequences based on the ultimate application of the hybridizing nucleotides or nucleosides.
[0065] As used herein, "complementary" sequences may also include non-Watson-Crick base pairs and / or base pairs formed by non-natural and alternative nucleotides or nucleosides, or may be formed entirely by them, as long as the above requirements for their hybridization ability are met. Such non-Watson-Crick base pairs include, but are not limited to, G:U wobble base pairing or Hoogstein base pairing. As described herein, the complementary sequence between an oligonucleotide and a target sequence comprises: an oligonucleotide or polynucleotide comprising a first nucleotide or nucleoside sequence and an oligonucleotide or polynucleotide comprising a second nucleotide or nucleoside sequence base pairing over the entire length of one or two nucleotide or nucleoside sequences. Such sequences may be referred to herein as "fully complementary" to each other. However, when the first sequence is referred to herein as "substantially complementary" to the second sequence, the two sequences may be fully complementary, or they may form one or more, but generally no more than 5, 4, 3 or 2 mismatched base pairs when hybridizing to obtain a duplex of up to 30 base pairs, while retaining the ability to hybridize under conditions most relevant to its final application (e.g., inhibition of gene expression via a ribonuclease H-mediated pathway). "Substantially complementary" can also refer to a polynucleotide that is substantially complementary to a continuous portion of an mRNA of interest (e.g., an mRNA encoding PCDH19). For example, if the sequence is substantially complementary to a non-interrupted portion of an mRNA encoding PCDH19, the polynucleotide is complementary to at least a portion of the PCDH19 mRNA.
[0066] As used herein, the term "complementary region" refers to a region on an oligonucleotide that is substantially complementary to all or part of a gene, primary transcript, sequence (e.g., a target sequence, such as a PCDH19 nucleotide sequence), or processed mRNA, so as to interfere with the expression of an endogenous gene (e.g., PCDH19). When the complementary region is not completely complementary to the target sequence, the mismatch may be in the interior or terminal regions of the molecule. Generally, the most tolerated mismatch is in the terminal region, such as within 5, 4, 3, or 2 nucleotides of the 5'- and / or 3'-end of the oligonucleotide.
[0067] " Percentage (%) sequence identity " with respect to reference polynucleotide or peptide sequence is defined as: after comparing sequence, and introducing room (gap) to realize maximum percentage sequence identity when necessary, the percentage of nucleic acid or amino acid in candidate sequence identical with nucleic acid or amino acid in reference polynucleotide or peptide sequence.Comparison for the purpose of determining nucleic acid or amino acid sequence identity percentage can be realized in various ways within the capabilities of those skilled in the art, for example, using publicly available computer software, such as BLAST, BLAST-2 or Megalign software.Those skilled in the art can determine the appropriate parameters for sequence alignment, including any algorithm required for maximum alignment realized on the entire length of the aligned sequence.For example, sequence comparison computer program BLAST can be used to generate percentage sequence identity value.As an example, given nucleic acid or amino acid sequence A and, and or for given nucleic acid or amino acid sequence B percentage sequence identity (it can be alternatively described as: given nucleic acid or amino acid sequence A, it and, and or for given nucleic acid or amino acid sequence B has certain percentage sequence identity) is calculated as follows:
[0068] 100 times (fraction X / Y)
[0069] wherein X is the number of nucleotides or amino acids that a sequence alignment program (e.g., BLAST) scores as identical matches in that program's alignment of A and B, and wherein Y is the total number of nucleic acids in B. It will be understood that when the length of nucleic acid or amino acid sequence A is not equal to the length of nucleic acid or amino acid sequence B, the percent sequence identity of A to B will not equal the percent sequence identity of B to A.
[0070] As used herein, "hybridization" refers to the pairing of substantially complementary nucleic acid chains, such as the pairing between the antisense oligonucleotides of the present invention and PCDH19 nucleotide sequences (e.g., mRNA or pre-mRNA transcripts). One mechanism of pairing involves hydrogen bonding between complementary nucleobases of nucleic acid chains, which may be Watson-Crick, Hoogsteen, or reverse Hoogsteen hydrogen bonding. For example, adenine and thymine or uracil are complementary nucleotides that pair by forming hydrogen bonds. Hybridization may occur under different circumstances. As used herein, reference to "specific hybridization" refers to hybridization of antisense oligonucleotides with a target region in a PCDH19 allele (e.g., a mutant PCDH19 allele), but not with the same target region in another PCDH19 allele (e.g., a wild-type PCDH19 allele).
[0071] As used herein, "agents that reduce the level and / or activity of PCDH19" refers to any polynucleotide agent (e.g., oligonucleotides, such as ASOs) that reduces the level of PCDH19 in a cell or subject or inhibits the expression of PCDH19. As used herein, the phrase "inhibiting the expression of PCDH19" includes inhibiting the expression of any PCDH19 gene (e.g., mouse PCDH19 gene, rat PCDH19 gene, monkey PCDH19 gene, or human PCDH19 gene) and PCDH19 gene variants or mutants encoding PCDH19 proteins. Therefore, in the context of genetically manipulating cells, cell populations, or organisms, the PCDH19 gene can be a wild-type PCDH19 gene, a mutant PCDH19 gene (e.g., an insertion, a deletion, a nonsense mutant, a missense mutant, a frameshift mutant), or a transgenic PCDH19 gene.
[0072] "Reducing the activity of PCDH19" refers to reducing the level of activity associated with PCDH19 (eg, ion channel function). The activity level of PCDH19 can be measured using any method known in the art (eg, using standard biophysical methods).
[0073] "Reducing the level of PCDH19" refers to reducing the amount of PCDH19 in a cell or subject, for example, by administering an oligonucleotide to a cell or subject. The level of PCDH19 can be measured using any method known in the art (e.g., by measuring the level of PCDH19 mRNA or the level of PCDH19 protein in a cell or subject).
[0074] As used herein, the term "inhibitor" refers to any agent that reduces the level and / or activity of a protein (e.g., PCDH19). Non-limiting examples of inhibitors include polynucleotides (e.g., oligonucleotides, such as ASOs). As used herein, the term "inhibiting" is used interchangeably with "reducing," "silencing," "downregulating," "suppressing," and other similar terms, and includes any degree of inhibition.
[0075] As used herein, the phrase "contacting a cell with an oligonucleotide," such as an oligonucleotide, includes contacting the cell in any possible manner. Contacting a cell with an oligonucleotide includes contacting the cell with an oligonucleotide in vitro or contacting the cell with an oligonucleotide in vivo. Contact may occur directly or indirectly. Thus, for example, the oligonucleotide may be brought into physical contact with the cell by the individual performing the method, or alternatively, the oligonucleotide agent may be placed in a condition that will allow or result in its subsequent contact with the cell.
[0076] Cells can be contacted in vitro or in vitro by, for example, incubating cells with oligonucleotides. Cells can be contacted in vitro or in vitro by, for example, injecting oligonucleotides into or near the tissue at the cell site, or by injecting oligonucleotide reagents into another region, such as bloodstream or subcutaneous space, so that reagents will subsequently arrive at the tissue at the cell site to be contacted, thereby contacting cells in vivo. For example, oligonucleotides can contain part and / or be coupled with a part, such as GalNAc3, which guides oligonucleotides to interested sites, such as liver. The combination of external, in vitro and in vivo contact methods is also possible. For example, cells can also be contacted with oligonucleotides in vitro and then transplanted into a subject.
[0077] In one embodiment, contacting a cell with an oligonucleotide includes "introducing" or "delivering an oligonucleotide into a cell" by promoting or affecting uptake or absorption into the cell. Absorption or uptake of the ASO can occur by unassisted diffusion or active cellular processes, or by adjuvants or devices. Introduction of the oligonucleotide into a cell can be in vitro, ex vivo, and / or in vivo. For example, for in vivo introduction, the oligonucleotide can be injected into a tissue site or administered systemically. In vitro introduction into a cell includes methods known in the art, such as electroporation and lipofection. Further methods are described herein below and / or are known in the art.
[0078] As used herein, "lipid nanoparticles" or "LNPs" are vesicles comprising a lipid layer that encapsulates pharmaceutically active molecules, such as nucleic acid molecules, e.g., oligonucleotides. LNPs refer to stable nucleic acid-lipid particles. LNPs typically contain cationic lipids, non-cationic lipids, and lipids that prevent particle aggregation (e.g., PEG-lipid conjugates). LNPs are described, e.g., in U.S. Pat. Nos. 6,858,225; 6,815,432; 8,158,601; and 8,058,069, the entire contents of which are hereby incorporated herein by reference.
[0079] As used herein, the term "liposome" refers to a vesicle composed of amphipathic lipids arranged in at least one double layer (e.g., a double layer or multiple double layers). Liposomes include unilamellar vesicles and multilamellar vesicles having a film and an aqueous interior formed by a lipophilic material. The aqueous portion contains an oligonucleotide composition. The lipophilic material separates the aqueous interior from the aqueous exterior, and the aqueous exterior does not generally include an oligonucleotide composition, although in some examples, an oligonucleotide composition may be included. Liposomes also include "steric stabilization" liposomes, as used herein, the term refers to a liposome comprising one or more special lipids, relative to a liposome lacking such special lipids, causing a circulation life growth when the special lipids are incorporated into the liposome.
[0080] A "micelle" is defined herein as a specific type of molecular assembly in which amphiphilic molecules are arranged in a spherical structure so that the hydrophobic portions of all molecules face inwards, with the hydrophilic portions in contact with the surrounding water. If the environment is hydrophobic, the opposite arrangement exists.
[0081] As used herein, the term "antisense" refers to a nucleic acid comprising an oligonucleotide or polynucleotide that is sufficiently complementary to all or a portion of a gene, primary transcript, or processed mRNA to interfere with the expression of an endogenous gene (e.g., PCDH19). "Complementary" polynucleotides are those that are capable of base pairing according to the standard Watson-Crick complementarity rules. Specifically, purines will base pair with pyrimidines to form a combination of guanine and cytosine pairing (G:C), and in the case of DNA, a combination of adenine and thymine pairing (A:T), or in the case of RNA, a combination of adenine and uracil pairing (A:U). It is understood that two polynucleotides can hybridize with each other even if they are not completely complementary to each other, provided that each polynucleotide has at least one region that is substantially complementary to the other.
[0082] As used herein, the terms "effective amount," "therapeutically effective amount," and "sufficient amount" of an agent that reduces the level and / or activity of PCDH19 described herein (e.g., in a cell or subject) refer to an amount sufficient to produce a beneficial or desired result (including a clinical result) when administered to a subject (including a human), and as such, an "effective amount" or a synonym thereof depends on the context in which it is applied. For example, in the context of treating a PCDH19-related disorder, the amount is the amount of an agent that reduces the level and / or activity of PCDH19 sufficient to achieve a therapeutic response compared to the response obtained without administering an agent that reduces the level and / or activity of PCDH19. The amount of a given agent that reduces the level and / or activity of PCDH19 described herein will correspond to an amount that will depend on various factors, such as a given agent, a pharmaceutical formulation, a route of administration, the type of disease or disorder, characteristics of the subject (e.g., age, sex, and / or weight), or the host being treated, etc., but can still be routinely determined by those skilled in the art. In addition, as used herein, the "therapeutically effective amount" of the agent that reduces the level and / or activity of PCDH19 disclosed herein is an amount that produces a beneficial or desired result in a subject compared to a control. As defined herein, the therapeutically effective amount of the agent that reduces the level and / or activity of PCDH19 disclosed herein can be easily determined by a person of ordinary skill in the art by conventional methods known in the art. The dosage regimen can be adjusted to provide the optimal therapeutic response.
[0083] As used herein, a "prophylactically effective amount" is intended to include an amount of such oligonucleotides, which, when administered to a subject suffering from or susceptible to a PCDH19-related disorder, is sufficient to prevent or improve one or more symptoms of the disease or disease. Improving a disease includes slowing the progression of the disease or reducing the severity of a subsequent disease. A "prophylactically effective amount" may vary, depending on the following: oligonucleotides, how the drug is administered, the degree of disease risk, and medical history, age, weight, family history, genetic composition, type of previous or concomitant treatment (if any), and other individual characteristics of the subject to be treated. A prophylactically effective amount also refers to, for example, an amount of an agent that reduces the level and / or activity of PCDH19 (e.g., in a cell or subject) refers to an amount sufficient to delay the onset of a PCDH19-related disorder when administered to a subject (including a human), as described herein, when compared to a predicted onset, a delay of at least 120 days, for example, at least 6 months, at least 12 months, at least 2 years, at least 3 years, at least 4 years, at least 5 years, at least 10 years or more.
[0084] A "therapeutically effective amount" or "prophylactically effective amount" also includes an amount of such an oligonucleotide (single administration or in multiple doses) that produces some desired local or systemic effect at a reasonable benefit / risk ratio applicable to any treatment. The oligonucleotides employed in the methods of the invention can be administered in sufficient amounts to produce a reasonable benefit / risk ratio applicable to such treatment.
[0085] As used herein, the term "a subject identified as having a PCDH19-related disorder" refers to a subject identified as having a PCDH19-related disorder or a molecular or pathological state, disease or condition associated therewith, such as identification of a PCDH19-related disorder or a symptom thereof, or refers to identification of a subject as having or suspected of having a PCDH19-related disorder and may benefit from a particular treatment regimen.
[0086] As used herein, "PCDH19-related disorders" refers to a class of genetic diseases or disorders characterized by abnormal PCDH19 function. PCDH19-related disorders include, for example, schizophrenia, autism, and epilepsy. For example, epilepsy can be an epileptic encephalopathy, including early infantile epileptic encephalopathy, such as early infantile epileptic encephalopathy type 9 (EIEE9).
[0087] "Determining the level of protein" refers to detecting protein or protein-encoding mRNA directly or indirectly by methods known in the art. "Direct determination" refers to performing a process (e.g., measuring or testing a sample, or "analyzing a sample", as the term is defined herein) to obtain a physical entity or value. "Indirect determination" refers to receiving a physical entity or value from another party or source (e.g., a third-party laboratory that directly obtains a physical entity or value). The method for measuring protein levels generally includes but is not limited to western blot, immunoblot, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), immunoprecipitation, immunofluorescence, surface plasmon resonance, chemiluminescence, fluorescence polarization, phosphorescence, immunohistochemical analysis, matrix-assisted laser desorption / ionization time of flight (MALDI-TOF) mass spectrometry, liquid chromatography (LC)-mass spectrometry, microcytometry, microscopy, fluorescence activated cell sorting (FACS) and flow cytometry, as well as determinations based on protein properties (including but not limited to enzyme activity or interactions with other protein partners). The method for measuring mRNA levels is known in the art.
[0088] "Level" refers to the level or activity of a protein or mRNA encoding a protein (e.g., PCDH19), optionally compared to a reference. A reference can be any useful reference as defined herein. A "reduced level" or "elevated level" of a protein refers to a reduction or increase in protein levels compared to a reference (e.g., a reduction or increase of about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100%, about 150%, about 200%, about 300%, about 400%, about 500% or more; a reduction or increase of more than about 100% or more compared to a reference). The level of protein can be expressed as mass / volume (e.g., g / dL, mg / mL, μg / mL, and ng / mL) or as a percentage of the total protein or mRNA in the sample.
[0089] As used herein, the term "pharmaceutical composition" means a composition containing a compound described herein formulated with a pharmaceutically acceptable excipient, and preferably manufactured or sold under the approval of a governmental regulatory agency as part of a therapeutic regimen for treating a mammalian disease. The pharmaceutical composition can be formulated, for example, for oral administration in a unit dosage form (e.g., tablets, capsules, caplets, gel capsules, or syrups); for topical administration (e.g., as a cream, gel, lotion, or ointment); for intravenous administration (e.g., as a sterile solution free of particulate emboli and in a solvent system suitable for intravenous use); for intrathecal injection; for intraventricular injection; for intraparenchymal injection; or any other pharmaceutically acceptable formulation.
[0090] As used herein, "pharmaceutically acceptable excipients" refers to any ingredient other than the compounds described herein (e.g., a carrier capable of suspending or dissolving the active compound) and having substantially non-toxic and non-inflammatory properties in a subject. Excipients may include, for example, antiadherents, antioxidants, binders, coatings, compression aids, disintegrants, dyes (pigments), emollients, emulsifiers, fillers (diluents), film formers or coatings, flavorings, fragrances, glidants (flow enhancers), lubricants, preservatives, printing inks, adsorbents, suspending or dispersing agents, sweeteners, and hydration water. Exemplary excipients include, but are not limited to, butylated hydroxytoluene (BHT), calcium carbonate, calcium phosphate (diabasic), calcium stearate, cross-linked carboxymethylcellulose, cross-linked polyvinyl pyrrolidone, citric acid, crospovidone, cysteine, ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methylparaben, microcrystalline cellulose, polyethylene glycol, polyvinyl pyrrolidone, povidone, pregelatinized starch, propylparaben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethylcellulose, sodium citrate, sodium starch glycolate, sorbitol, starch (corn), stearic acid, sucrose, talc, titanium dioxide, vitamin A, vitamin E, vitamin C, and xylitol.
[0091] As used herein, the term "pharmaceutically acceptable salt" refers to any pharmaceutically acceptable salt of any compound described herein. For example, pharmaceutically acceptable salts of any compound described herein include those salts within the scope of reasonable medical judgment, which are suitable for contact with human and animal tissues without excessive toxicity, irritation, allergic reaction, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, pharmaceutically acceptable salts are described in: Berge et al., J. Pharmaceutical Sciences 66: 1-19, 1977 and Pharmaceutical Salts: Properties, Selection, and Use, (P. H. Stahl and C. G. Wermuth, eds.), Wiley-VCH, 2008. Salts can be prepared in situ during the final isolation and purification of the compounds described herein, or they can be prepared separately by reacting the free base with a suitable organic acid.
[0092] The compounds described herein may have ionizable groups so that they can be prepared as pharmaceutically acceptable salts. These salts may be acid addition salts involving inorganic or organic acids, or, in the case of acidic forms of the compounds described herein, these salts may be prepared from inorganic or organic bases. Typically, these compounds are prepared or used as pharmaceutically acceptable salts, prepared as addition products of pharmaceutically acceptable acids or bases. Suitable pharmaceutically acceptable acids and bases and methods for preparing suitable salts are well known in the art. Salts may be prepared from pharmaceutically acceptable non-toxic acids and bases, including inorganic and organic acids and bases. Representative acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, gluconoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate, undecanoate, and valerate. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, and magnesium, as well as nontoxic ammonium, quaternary ammonium, and amine cations including, but not limited to, ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, and ethylamine.
[0093] "Reference" refers to any useful reference for comparing protein or mRNA levels or activity. A reference can be any sample, standard, standard curve or level for comparison purposes. A reference can be a normal reference sample or reference standard or level. A "reference sample" can be, for example, a control, such as a predetermined negative control value, such as a "normal control" or a previous sample collected from the same subject; a sample from a normal healthy subject, such as a normal cell or normal tissue; a sample (such as a cell or tissue) from a subject without a disease; a sample from a subject diagnosed with a disease but not yet treated with a compound described herein; a sample from a subject treated with a compound described herein; or a sample of a purified protein (such as any purified protein described herein) of known normal concentration. "Reference standard or level" refers to a value or number derived from a reference sample. "Normal control value" is a predetermined value indicating a non-disease state, such as an expected value for a healthy control subject. Typically, a normal control value is expressed as a range ("between X and Y"), a high threshold ("not higher than X"), or a low threshold ("not lower than X"). For a specific biomarker, a subject whose measured value is within the normal control value is generally referred to as being within the "normal range" of the biomarker. A normal reference standard or level can be a normal subject from a patient who does not have a disease or disorder (e.g., a PCDH19-related disorder); a value or number for a subject who has been treated with a compound described herein. In a preferred embodiment, the reference sample, standard, or level is matched to the sample subject sample by at least one of the following criteria: age, weight, sex, disease stage, and overall health. A standard curve of the level of a purified protein (e.g., any purified protein described herein) within the normal reference range can also be used as a reference.
[0094] As used herein, the term "subject" refers to any organism to which the compositions of the present invention may be applied, for example, for experimental, diagnostic, preventive and / or therapeutic purposes. Typical subjects include any animal (e.g., mammals, such as mice, rats, rabbits, non-human primates and humans). Subjects may seek or need treatment, require treatment, are being treated, will be treated in the future, or are receiving trained professionals for the care of a particular disease or condition or an animal. Subjects can be of any age, such as newborns, neonates, infants, toddlers, teenagers or adults. Subjects can be in utero.
[0095] As used herein, the terms "treat," "treated," or "treating" refer to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or mitigate (alleviate) an undesirable physiological condition, disorder, or disease, or to obtain a beneficial or desired clinical result. Beneficial or desired clinical results include, but are not limited to, relief of symptoms; reduction in the extent of a condition, disorder, or disease; stabilization (i.e., not worsening) of the condition, disorder, or disease state; delay in onset or slowing of the progression of a condition, disorder, or disease; amelioration or remission (whether partial or total), whether detectable or undetectable, of a condition, disorder, or disease state; improvement in at least one measurable physical parameter that is not necessarily discernible by the subject; or enhancement or amelioration of a condition, disorder, or disease. Treatment includes inducing a clinically significant response without producing excessive levels of side effects. Treatment also includes prolonged survival compared to the expected survival if not receiving treatment.
[0096] As used herein, the terms "variant" and "derivative" are used interchangeably and refer to naturally occurring, synthetic and semisynthetic analogs of compounds, peptides, proteins or other substances described herein. Variants or derivatives of compounds, peptides, proteins or other substances described herein may retain or improve the biological activity of the original material.
[0097] The details of one or more embodiments of the invention are set forth in the description below. Other features, objects, and advantages of the invention will be apparent from the description and from the claims. DETAILED DESCRIPTION
[0098] According to an embodiment of the present invention, the level and / or activity of PCDH19 in the cell that is inhibited or consumed is effectively used to treat PCDH19-related diseases. Therefore, the present invention particularly relates to useful compositions and methods for treating PCDH19-related diseases (e.g., in a subject in need). The present invention particularly relates to single-stranded oligonucleotides targeting the PCDH19 gene. Oligonucleotides (e.g., chemically modified oligonucleotides) can be applied to subjects suffering from PCDH19-related diseases (e.g., epilepsy, schizophrenia, and autism) to facilitate the treatment of PCDH19-related diseases, alleviate the symptoms of PCDH19-related diseases, or prevent PCDH19-related diseases. Oligonucleotides are antisense (e.g., at least partially complementary) to the target region of PCDH19 (e.g., PCDH19 mRNA, including precursor mRNA and processed mRNA). After administration, oligonucleotides reduce the level, expression, and / or activity of PCDH19 (e.g., PCDH19 mRNA and / or protein), thereby providing a therapeutic effect for subjects suffering from PCDH19-related diseases.
[0099] PCDH19-related disorders
[0100] PCDH19 is a cadherin family protein that is primarily expressed in the developing brain. The gene encoding PCDH19 is located at position 22.1 on the long (q) arm of chromosome X. Although its function has not been fully elucidated, it is believed to play a role in calcium-dependent cell adhesion. The full-length human processed PCDH19 mRNA is 9765 nucleotides long, and exon 2 is alternatively spliced.
[0101] Exemplary human PCDH19 genes include those having nucleotide sequences set forth in NCBI reference numbers NC_000023.11 (SEQ ID NO: 1), NG_021319.1, NM_001105243.1, NM_001184880.1, and NM_020766.2, and variants thereof, including variants containing single nucleotide polymorphisms, such as those described in various publicly available databases (e.g., the Genome Aggregation Database (gnomAD) (http: / / gnomad.broadinstitute.org / ). By way of example only, a PCDH19 variant can have at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 1.
[0102] Mutations in PCDH19 (e.g., missense or nonsense mutations) are associated with schizophrenia, autism, and specific forms of epilepsy (e.g., early infantile epileptic encephalopathy type 9 (EIEE9)). Since PCDH19 is located on the X chromosome, EIEE9 is associated with a unique X-linked inheritance pattern. X-linked mutations typically affect males, but not carrier females. However, EIEE9 does not spread to males, but only affects carrier females. EIEE9 is only associated with females, and male subjects affected by chimeric PCDH19 expression are also shown to experience cognitive impairment and / or epilepsy. Chimeras relate to the presence of two or more cell populations expressing different genotypes of PCDH19. Generally, mutations occur in specific cells (e.g., de novo) and are only passed to daughter cells during division. Known mutations associated with PCDH19-related diseases include mutations encoding N340S, E307K, V441E, Q85X, N557K, D594H, S671X, L677fsx717, I119fsX122, and P364fsX375. Other known mutations associated with PCDH19-related diseases are listed in Table 1 below.
[0103] Compositions and methods described herein can be used to treat subjects with one or more of these mutations. Any PCDH19-related disorders described herein (e.g., epilepsy, autism, and schizophrenia) can be treated by administering oligonucleotides as described herein (e.g., chemically modified oligonucleotides, e.g., ASOs) to alleviate or eliminate the symptoms of the disorder.
[0104]
[0105]
[0106]
[0107]
[0108]
[0109]
[0110]
[0111]
[0112]
[0113] Oligonucleotide reagents
[0114] The reagents described herein that reduce the level and / or activity (e.g., abnormal activity) of PCDH19 in cells can be, for example, polynucleotides, such as oligonucleotides. These reagents reduce the level of activity (e.g., binding activity) associated with PCDH19 or related downstream effects in cells or subjects, or reduce the level of PCDH19.
[0115] In some embodiments, the reagent that reduces the level and / or activity of PCDH19 is a polynucleotide. In some embodiments, the polynucleotide is a single-stranded oligonucleotide, such as a single-stranded oligonucleotide that works through a ribonuclease H-mediated approach. Oligonucleotides include DNA and DNA / RNA chimeric molecules, typically about 10 to 30 nucleotides in length, which interact with the hydrogen bonding of the nucleotide bases of the target sequence (eg PCDH19) to identify the polynucleotide target sequence or sequence portion. Oligonucleotide molecules can reduce the expression level (eg protein level or mRNA level) of PCDH19. For example, oligonucleotides include oligonucleotides targeting full-length PCDH19. In some embodiments, oligonucleotide molecules recruit ribonuclease H enzymes, resulting in target mRNA degradation.
[0116] In some embodiments, the oligonucleotide reduces the level and / or activity of a positive regulator of function. In other embodiments, the oligonucleotide increases the level and / or activity of an inhibitor of a positive regulator of function. In some embodiments, the oligonucleotide increases the level and / or activity of a negative regulator of function.
[0117] In some embodiments, the oligonucleotide reduces the level and / or activity or function of PCDH19. In some embodiments, the oligonucleotide inhibits the expression of PCDH19. In other embodiments, the oligonucleotide increases the degradation of PCDH19 and / or reduces the stability (i.e., half-life) of PCDH19 (e.g., mRNA). The oligonucleotide can be chemically synthesized.
[0118] Oligonucleotides include oligonucleotides having a complementary region (e.g., a continuous nucleobase region) that is complementary to at least a portion of the mRNA formed in the expression of the PCDH19 gene. The length of the complementary region can be about 30 nucleotides or less (e.g., a length of about 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11 or 10 nucleotides or less). When contacted with a cell expressing the PCDH19 gene, the oligonucleotide can inhibit the expression of the PCDH19 gene (e.g., a human, primate, non-primate or avian PCDH19 gene) by at least about 10% (e.g., 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97%, 99% or 100%), as determined by, for example, PCR-based or branched DNA (bDNA) methods, or by protein-based methods (e.g., by immunofluorescence analysis) using, for example, western blotting or flow cytometry techniques.
[0119] Similarly, the region complementary to the target sequence can be between 10 and 30 linked nucleosides in length, for example, 10-29, 10-28, 10-27, 10-26, 10-25, 10-24, 10-23, 10-22, 10-21, 10-20, 10-19, 10-18, 10-17, 10-16, 10-18, 10-19, 10-20, 10-21 ... 0-15, 10-14, 10-13, 10-12, 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28 , 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20 In some embodiments, the present invention relates to a nucleic acid sequence of at least 20 amino acids, preferably at least 20 amino acids, preferably at least 20 amino acids, preferably at least 20 amino acids, preferably at least 20 amino acids, preferably at least 20 amino acids, preferably at least 20 amino acids, preferably at least 20 amino acids, preferably at least 20 amino acids, preferably at least 20 amino acids, preferably at least 20 amino acids, preferably at least 20 amino acids, preferably at least 20 amino acids, preferably at least 20 amino acids, preferably at least 20 amino acids, preferably at least 20 amino acids, preferably at least 20 amino acids, preferably at least 20 amino acids, preferably at least 20 amino acids, preferably at least 20 amino acids,
[0120] The oligonucleotide may comprise an isomeric portion of a target region of a PCDH19 gene (e.g., a pre-mRNA transcript or mRNA transcript of PCDH19) that is at least 80% (e.g., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) complementary to the region. The mRNA transcript or pre-mRNA transcript may contain a mutation (e.g., the subject is heterozygous (e.g., female) or hemizygous (e.g., male) for the mutation). The oligonucleotide may selectively target an mRNA or pre-mRNA containing a mutation (e.g., an allele-specific ASO). The oligonucleotide may target both mutant alleles and wild-type alleles.
[0121] As discussed further below, oligonucleotides can be synthesized by standard methods known in the art, such as by using an automated DNA synthesizer, such as those commercially available from, for example, Biosearch, Applied Biosystems, Inc.
[0122] Oligonucleotide compounds can be prepared using solution phase or solid phase organic synthesis or both. The advantage provided by organic synthesis is that oligonucleotides comprising non-natural or alternative nucleotides can be easily prepared. Single-stranded oligonucleotides of the present invention can be prepared using solution phase or solid phase organic synthesis or both.
[0123] In one aspect, the oligonucleotides of the invention comprise a region of at least 10 (e.g., 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more) consecutive nucleobases, which are at least 80% (e.g., at least 85%, at least 90%, at least 95%, or at least 99%) complementary to at least 10 consecutive nucleotides of the PCDH19 gene. In some embodiments, the oligonucleotide comprises a sequence complementary to at least 17 consecutive nucleotides, 19-23 consecutive nucleotides, 19 consecutive nucleotides, or 20 adjacent nucleotides of the PCDH19 gene. In this regard, the sequence is substantially complementary to the mRNA sequence produced in the expression of the PCDH19 gene.
[0124] In some embodiments, the oligonucleotide of the present invention or its continuous nucleotide region has a gapmer design or structure, also referred to herein as only "gapmer". In the gapmer structure, the oligonucleotide comprises at least three different structural regions: 5'-wing, gap and 3'-wing in the "5->3" direction. In this design, 5' and 3' wing regions (also referred to as flanking regions) comprise at least one alternative nucleoside adjacent to the gap region, and in some embodiments, may comprise a continuous segment of 2-7 alternative nucleosides, or a continuous segment of alternative nucleosides and DNA nucleosides (mixed wings comprise both alternative nucleosides and DNA nucleosides). The length of the 5'-wing region may be a length of at least two nucleosides (e.g., a length of at least 2, at least 3, at least 4, at least 5 or more nucleosides). The length of the 3'-wing region may be a length of at least two nucleosides (e.g., a length of at least 2, at least 3, at least 4, at least 5 or more nucleosides). In terms of the number of nucleosides it comprises, the 5' and 3' wing regions may be symmetrical or asymmetrical. In some embodiments, the gap region comprises about 10 nucleosides and is flanked by 5' and 3' wings, each wing comprising about 5 nucleosides, also referred to as a 5-10-5 gapmer.
[0125] Therefore, the nucleosides of the 5' wing region and the 3' wing region adjacent to the gap region are alternative nucleosides, such as 2' alternative nucleosides. The gap region comprises a continuous segment of nucleotides, and when the oligonucleotide forms a double strand with the PCDH19 target nucleic acid, the nucleotides are capable of recruiting ribonuclease H. In some embodiments, the gap region comprises a continuous segment of 5-16 DNA nucleosides. In other embodiments, the gap region comprises a region of at least 10 continuous nucleobases, and the region has at least 80% (e.g., at least 85%, at least 90%, at least 95% or at least 99%) complementarity with the PCDH19 gene. In some embodiments, gapmer comprises a region complementary to at least 17 continuous nucleotides, 19-23 continuous nucleotides, or 19 continuous nucleotides of the PCDH19 gene. Gapmer is complementary to the PCDH19 target nucleic acid, and therefore can be a continuous nucleoside region of an oligonucleotide.
[0126] 5' and 3' wing regions are flanked by the 5' and 3' ends of the gap region, and may include one or more alternative nucleosides that enhance affinity. In some embodiments, the 5' and / or 3' wing comprises at least one 2'-O-methoxyethyl (MOE) nucleoside, preferably at least two MOE nucleosides. In some embodiments, the 5' wing comprises at least one MOE nucleoside. In some embodiments, both the 5' and 3' wing regions comprise MOE nucleosides. In some embodiments, all nucleosides in the wing region are MOE nucleosides. In other embodiments, the wing region may comprise both MOE nucleosides and other nucleosides (mixed wings), such as DNA nucleosides and / or non-MOE alternative nucleosides, such as bicyclic nucleosides (BNA) (e.g., LNA nucleosides or cET nucleosides) or other 2' substituted nucleosides. In this case, the gap is defined as a continuous sequence of at least 5 nucleosides (e.g., 5-16 DNA nucleosides) that recruit ribonuclease H, and its 5' and 3' end flanks are alternative nucleosides that enhance affinity, such as MOE nucleosides.
[0127] In other embodiments, the 5' and / or 3' wing comprises at least one BNA (e.g., at least one LNA nucleoside or cET nucleoside), preferably at least 2 bicyclic nucleosides. In some embodiments, the 5' wing comprises at least one BNA. In some embodiments, both the 5' and 3' wing regions comprise BNA. In some embodiments, all nucleosides in the wing region are BNA. In other embodiments, the wing region may comprise both BNA and other nucleosides (mixed wings), such as DNA nucleosides and / or non-BNA alternative nucleosides, such as 2' substituted nucleosides. In this case, the gap is defined as a continuous sequence of at least five nucleosides (e.g., 5-16 DNA nucleosides) that recruit ribonuclease H, and its 5' and 3' end flanks are alternative nucleosides with enhanced affinity, such as BNA, such as LNA, such as β-D-oxy-LNA.
[0128] The 5' flank or 5' wing connected to the 5' end of the gap region comprises, contains at least one alternative sugar moiety (e.g., at least three, at least four, at least five, at least six, at least seven or more alternative sugar moieties) or consists of it. In some embodiments, the wing region comprises 1 to 7 alternative nuclear bases, such as 2 to 6 alternative nuclear bases, such as 2 to 5 alternative nuclear bases, such as 2 to 4 alternative nuclear bases, such as 1 to 3 alternative nuclear bases, such as one, two, three or four alternative nuclear bases, or consists of it. In some embodiments, the wing region comprises at least one alternative nucleoside bond (e.g., at least three, at least four, at least five, at least six, at least seven or more alternative nucleoside bonds) or consists of it.
[0129] The 3' flank or 3' wing connected to the 3' end of the gap region comprises, contains at least one alternative sugar moiety (e.g., at least three, at least four, at least five, at least six, at least seven or more alternative sugar moieties) or consists of it. In some embodiments, the wing region comprises 1 to 7 alternative nuclear bases, such as 2 to 6 alternative nuclear bases, such as 2 to 5 alternative nuclear bases, such as 2 to 4 alternative nuclear bases, such as 1 to 3 alternative nuclear bases, such as one, two, three or four alternative nuclear bases, or consists of it. In some embodiments, the wing region comprises at least one alternative nucleoside bond (e.g., at least three, at least four, at least five, at least six, at least seven or more alternative nucleoside bonds) or consists of it.
[0130] In embodiments, one or more or all alternative sugar moieties in the wing are 2' alternative sugar moieties.
[0131] In a further embodiment, the one or more 2' alternative sugar moieties in the wing are selected from a 2'-O-alkyl sugar moiety, a 2'-O-methyl sugar moiety, a 2'-amino sugar moiety, a 2'-fluoro sugar moiety, a 2'-alkoxy sugar moiety, a MOE sugar moiety, an LNA sugar moiety, an arabinoic acid (ANA) sugar moiety, and a 2'-fluoro-ANA sugar moiety.
[0132] In one embodiment of the invention, all alternative nucleosides in the wing region are bicyclic nucleosides. In a further embodiment, the bicyclic nucleosides in the wing region are independently selected from oxy-LNA, thio-LNA, amino-LNA, cET and / or ENA or a combination thereof in β-D or α-L configuration.
[0133] In some embodiments, one or more alternative nucleoside bonds in the wing region are thiophosphate nucleoside bonds. In some embodiments, the thiophosphate bond is a stereochemically pure thiophosphate bond. In some embodiments, the thiophosphate bond is a Sp thiophosphate bond. In other embodiments, the thiophosphate bond is an Rp thiophosphate bond. In some embodiments, the alternative nucleoside bond is a 2'-alkoxy nucleoside bond. In other embodiments, the alternative nucleoside bond is an alkyl phosphate nucleoside bond.
[0134] The gap region may comprise, contain or consist of at least 5-16 consecutive DNA nucleosides capable of recruiting ribonuclease H. In some embodiments, all nucleosides in the gap region are DNA units. In further embodiments, the gap region may consist of a mixture of DNA and other nucleosides capable of mediating ribonuclease H cleavage. In some embodiments, at least 50% of the nucleosides in the gap region are DNA, such as at least 60%, at least 70%, or at least 80%, or at least 90% are DNA.
[0135] Oligonucleotide of the present invention comprises a continuous region complementary to the target nucleic acid. In some embodiments, the oligonucleotide may further comprise the nucleosides that are positioned at the 5' and 3' wing regions 5' and / or 3' extra connections. The nucleosides that these extra connections can be connected respectively with the 5' end of the 5' wing region or the 3' end of the 3' wing region. Extra nucleosides can form a part for a continuous sequence complementary to the target nucleic acid in some embodiments, or in other embodiments, can be non-complementary with the target nucleic acid.
[0136] In any one or both of 5' and 3' wing regions, comprising extra nucleosides can independently comprise one, two, three, four or five extra nucleotides, and the extra nucleotides can be complementary or non-complementary to the target nucleic acid. In this regard, the oligonucleotide of the present invention can comprise a continuous sequence that can regulate the target in some embodiments, and the continuous sequence is an extra nucleotide at 5' and / or 3' terminal flanks. Such extra nucleosides can be used as a biologically cleavable joint sensitive to nucleases, and therefore can be used to connect a functional group (such as a conjugated moiety) to the oligonucleotide of the present invention. In some embodiments, extra 5' and / or 3' terminal nucleosides are connected with phosphodiester bonds, and can be DNA or RNA. In another embodiment, extra 5' and / or 3' terminal nucleosides are alternative nucleosides, and the alternative nucleosides can, for example, be included to enhance nuclease stability or be easy to synthesize.
[0137] In other embodiments, the oligonucleotides of the invention employ an "altimer" design and comprise alternating 2'-fluoro-ANA and DNA regions, which alternate every three nucleosides. Altimer oligonucleotides are discussed in more detail in Min et al., Bioorganic & Medicinal Chemistry Letters, 2002, 12(18): 2651-2654 and Kalota et al., Nuc. Acid Res. 2006, 34(2): 451-61 (incorporated herein by reference).
[0138] In other embodiments, the oligonucleotides of the invention employ a "hemimer" design and comprise a single 2' modified wing segment adjacent to a gap region (either on the 5' or 3' side). Hemimer oligonucleotides are discussed in more detail in Geary et al., 2001, J. Pharm. Exp. Therap., 296: 898-904 (incorporated herein by reference).
[0139] In some embodiments, the oligonucleotide has a nucleic acid sequence that has at least 50% (e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) sequence identity to an equal length target sequence of PCDH19. In some embodiments, the oligonucleotide has a nucleic acid sequence that has at least 85% sequence identity to an equal length target sequence of PCDH19.
[0140] It will be understood that although the ASO sequences are described as unmodified and / or unconjugated sequences, the nucleosides of the oligonucleotides of the invention (e.g., the oligonucleotides of the invention) may comprise any sequence as alternative nucleosides and / or conjugated as described in detail below.
[0141] It is fully known to the technician that oligonucleotides with structures between about 18-20 base pairs can be particularly effective in inducing ribonuclease H-mediated degradation. However, it is understood that shorter or longer oligonucleotides can also be effective. In the above-mentioned embodiments, due to the properties of the oligonucleotide sequences provided herein, oligonucleotides as described herein can be included. It can be reasonably expected that, compared with the above-mentioned oligonucleotides, shorter oligonucleotides with only a few connected nucleosides at one or both ends can be similarly effective. Therefore, it is envisioned that such oligonucleotides are within the scope of the present invention, which have sequences of at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more continuously connected nucleosides derived from one of the sequences provided herein, and the difference between the ability to inhibit PCDH19 gene expression and the oligonucleotides comprising the complete sequence does not exceed about 5, 10, 15, 20, 25 or 30% inhibition.
[0142] The oligonucleotides described herein can function by nuclease-mediated degradation of a target nucleic acid, wherein the oligonucleotides of the invention are capable of recruiting nucleases, particularly endonucleases, preferably endoribonucleases (ribonucleases), such as RNase H. Exemplary of oligonucleotide designs that function by a nuclease-mediated mechanism are oligonucleotides that typically comprise a region of at least 5 or 6 DNA nucleosides and are flanked on one or both sides by alternative affinity-enhancing nucleosides, such as gapmers, headmers, and tailmers.
[0143] The RNase H activity of an oligonucleotide refers to its ability to recruit RNase H when forming a duplex with a complementary RNA molecule. WO01 / 23613 provides an in vitro method for determining RNase H activity, which can be used to determine the ability to recruit RNase H. Generally, an oligonucleotide is considered to be able to recruit RNase H if, when provided with a complementary target nucleic acid sequence, the initial rate of the oligonucleotide, as measured in pmol / l / min, and using the methods provided in Examples 91-95 of WO01 / 23613 (incorporated herein by reference), is at least 5%, such as at least 10% or more than 20% of the initial rate determined when using the following oligonucleotide: the oligonucleotide has the same base sequence as the modified oligonucleotide being tested, but contains only DNA monomers, and all monomers in the oligonucleotide have phosphorothioate bonds between them.
[0144] In addition, the oligonucleotides described herein identify sites in the PCDH19 transcript that are susceptible to RNase H-mediated cleavage. Therefore, the present invention further particularly relates to oligonucleotides targeting the site. As used herein, if the oligonucleotide promotes the cleavage of the transcript at any position within a specific site, the oligonucleotide is said to be targeted to the specific site of the RNA transcript. Such oligonucleotides will generally contain at least about 5-10 consecutively connected nucleosides from one of the sequences provided herein, coupled to additionally connected nucleoside sequences obtained from a region where the selected sequence is continuous in the PCDH19 gene.
[0145] Inhibitory oligonucleotides can be designed by methods well known in the art.While target sequences are generally about 10-30 linked nucleosides in length, within this range there is great variability in the suitability of a particular sequence to direct cleavage of any given target RNA.
[0146] Oligonucleotides having sufficient homology to provide the sequence specificity required to uniquely degrade any RNA can be designed using procedures known in the art.
[0147] Several designed species can also be systematically tested according to the teachings provided herein to optimize inhibitory oligonucleotide sequences. Considerations when designing interfering oligonucleotides include, but are not limited to, biophysical, thermodynamic and structural considerations, base preferences at specific positions and homology. The manufacture and use of inhibitory therapeutic agents based on non-coding oligonucleotides are also known in the art.
[0148] The various software packages and guides listed herein provide guidance for identifying the best target sequence for any given gene target, but an empirical approach may also be employed, wherein a "window" or "mask" of a given size (as a non-limiting example, 21 nucleotides) is literally or figuratively (including, for example, in a computer) placed on the target RNA sequence to identify sequences within a size range that can be used as target sequences. By incrementally moving the sequence "window" one nucleotide upstream or downstream of the initial target sequence position, the next potential target sequence can be identified until a complete set of possible sequences is identified for any given target size selected. This process is coupled with systematic synthesis and testing of the identified sequences (using assays as described herein or known in the art to identify those sequences that perform best), and those RNA sequences that mediate the best inhibition of target gene expression when targeted with an oligonucleotide reagent can be identified. Thus, while the sequences identified herein represent effective target sequences, it is contemplated that further optimization of inhibition efficiency can be achieved by "walking" the "window" one nucleotide upstream or downstream of a given sequence to identify sequences with the same or better inhibition characteristics.
[0149] In addition, it is contemplated that for any sequence identified herein, further optimization can be achieved by systematically adding or deleting linked nucleosides to generate longer or shorter sequences and testing those generated sequences by walking windows of longer or shorter size up or down the target RNA from that point. Likewise, coupling this method of generating new candidate targets with testing of oligonucleotide effectiveness based on those target sequences in inhibition assays known in the art and / or as described herein can further improve inhibition efficiency.
[0150] In addition, such optimized sequences can be adjusted by, for example, introducing alternative nucleosides as described herein or known in the art, alternative sugar moieties and / or alternative nucleosides bonds, including alternative nucleosides as known in the art and / or discussed herein, alternative sugar moieties and / or alternative nucleosides bonds, further optimizing the molecule as expression inhibitor (for example, increasing serum stability or circulation half-life, increasing thermal stability, enhancing transmembrane delivery, targeting to a specific location or cell type, increasing the interaction with silencing pathway enzymes, increasing release from endosomes). Oligonucleotide reagents as described herein can contain one or more mispairings with target sequences. In one embodiment, oligonucleotide as described herein contains no more than 3 mispairings. If oligonucleotide contains a mispairing with the target sequence, then preferably the mispairing region is not located at the center of the complementary region. If oligonucleotide contains a mispairing with the target sequence, then preferably the mispairing is limited to the last 5 nucleotides at the 5' or 3' ends of the complementary region. For example, for an oligonucleotide reagent of 30 linked nucleosides, the contiguous nucleobase region complementary to the PCDH19 gene region generally does not contain any mismatches within the central 5-10 linked nucleosides. The methods described herein or methods known in the art can be used to determine whether an oligonucleotide containing a mismatch with a target sequence effectively inhibits the expression of the PCDH19 gene. It is important to consider the efficacy of oligonucleotides with mismatches in inhibiting PCDH19 gene expression, particularly if it is known that a specific complementary region in the PCDH19 gene has polymorphic sequence variations within a population.
[0151] Conventional techniques can be used to complete the construction of vectors for expressing polynucleotides for use in the present invention, and it is not necessary to explain the conventional techniques in detail to those of ordinary skill in the art. In order to generate an effective expression vector, it is necessary to have regulatory sequences that control the expression of the polynucleotides. These regulatory sequences include promoter and enhancer sequences, and are affected by specific cytokines that interact with these sequences, and are well known in the art.
[0152] Alternative oligonucleotides
[0153] In one embodiment, the nucleosides or internucleoside bonds of one or more connections of the oligonucleotide of the present invention are naturally occurring, and do not include chemical modifications and / or conjugations such as known in the art and described herein. In another embodiment, the one or more connection nucleosides or internucleoside bonds of the oligonucleotide of the present invention are chemically modified to enhance stability or other beneficial features. Not bound by theory, it is believed that some modifications can increase nuclease tolerance and / or serum stability, or reduce immunogenicity. For example, the oligonucleotide of the present invention can contain nucleotides (such as adenine, thymidine, guanosine, cytidine, uridine or inosine) found to be naturally present in DNA or RNA, or can contain one or more components (such as core bases, sugar or phosphate linker moieties) of nucleotides with one or more chemically modified alternative nucleosides or internucleoside bonds. The oligonucleotides of the invention may be linked to each other via naturally occurring phosphodiester bonds, or may contain alternative bonds (e.g., covalent linkages via phosphorothioate bonds (e.g., Sp phosphorothioate bonds or Rp phosphorothioate bonds), 3'-methylenephosphonate bonds, 5'-methylenephosphonate bonds, 3'-phosphoramide bonds, 2'-5' phosphodiester bonds, guanidine bonds, S-methylthiourea bonds, 2'-alkoxy bonds, alkylphosphonate bonds, or peptide bonds).
[0154] In certain embodiments of the present invention, substantially all nucleosides or internucleoside bonds of the oligonucleotide of the present invention are alternative nucleosides. In other embodiments of the present invention, all nucleosides or internucleoside bonds of the oligonucleotide of the present invention are alternative nucleosides. The oligonucleotide of the present invention, wherein "substantially all nucleosides are alternative nucleosides", is a major part but not completely modified, and may include no more than five, four, three, two or one naturally occurring nucleosides. In other embodiments of the present invention, the oligonucleotide of the present invention may include no more than five, four, three, two or one alternative nucleosides.
[0155] Nucleic acids particularly contemplated by the present invention may be synthesized and / or modified by methods recognized in the art, such as those described in "Current protocols in nucleic acid chemistry," Beaucage, SL et al. (eds.), John Wiley & Sons, Inc., New York, NY, USA, which are incorporated herein by reference. Alternative nucleotides and nucleosides include those with modifications, such as terminal modifications, such as 5' terminal modifications (phosphorylation, conjugation, reverse bond) or 3' terminal modifications (conjugation, DNA nucleotides, reverse bond, etc.); base modifications, such as replacement with stabilized bases, destabilized bases, or bases that pair with an extended partner repertoire, removal of bases (abasic nucleotides) or conjugation of bases; sugar modifications (e.g., at the 2' or 4' position) or replacement of sugars; and / or backbone modifications, including modification or replacement of phosphodiester bonds. Nucleobase can also be isobase, wherein nucleobase moves to different positions (such as C2, C3, C4 or C5) from the C1 position of sugar part.The specific example of useful oligonucleotide compound in the embodiment described herein includes, but is not limited to, containing modified skeleton or not having the alternative nucleoside of natural internucleoside bond.The nucleotide and nucleoside with modified skeleton include, especially, those nucleotide and nucleoside without phosphorus atom in skeleton.For the purpose of this specification, and as sometimes mentioned in this area, the alternative RNA without phosphorus atom in its internucleoside skeleton can also be considered as oligonucleoside.In some embodiments, oligonucleotide will have phosphorus atom in its internucleoside skeleton.
[0156] Alternative internucleoside bonds include, for example, phosphorothioate bonds, chiral phosphorothioate bonds, phosphorodithioate bonds, phosphotriester bonds, aminoalkylphosphotriester bonds, methyl and other alkylphosphonate bonds (including 3'-alkylenephosphonate bonds) and chiral phosphonate bonds, phosphinate bonds, phosphoramide bonds (including 3'-aminophosphoramide bonds and aminoalkylphosphoramide bonds), thiophosphoramide bonds, thioalkylphosphonate bonds, thioalkylphosphotriester bonds and borophosphate bonds with normal 3'-5' bonds, 2'-5' connection analogs of these bonds, and those bonds with reverse polarity, wherein adjacent nucleoside units are connected to 3'-5' to 5'-3' or 2'-5' to 5'-2'. Various salts, mixed salts and free acid forms are also included.
[0157] Representative U.S. patents that teach the preparation of the above phosphorus-containing bonds include, but are not limited to, U.S. Patent Nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,195; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,316; 5,550,111; 5,563,253; 5,571,799; 5, 587,361; 5,625,050; 6,028,188; 6,124,445; 6,160,109; 6,169,170; 6,172,209; 6,239,265; 6,277,603; 6,326,199; 6,346,614; 6,444,423; 6,531,590; 6,5 34,639; 6,608,035; 6,683,167; 6,858,715; 6,867,294; 6,878,805; 7,015,315; 7,041,816; 7,273,933; 7,321,029; and U.S. Patent No. RE39464, each of which is hereby incorporated by reference in its entirety.
[0158] The alternative nucleoside bonds that do not include a phosphorus atom have a backbone formed by short-chain alkyl or cycloalkyl nucleoside bonds, mixed heteroatoms and alkyl or cycloalkyl nucleoside bonds, or one or more short-chain heteroatoms or heterocyclic nucleoside bonds. These backbones include those with morpholinyl bonds (partially formed by the sugar portion of the nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formyl and thioformyl backbones; methyleneformyl and thioformyl backbones; olefin-containing backbones; aminosulfonic acid backbones; methyleneimino and methylenehydrazine backbones; sulfonic acid and sulfonamide backbones; amide backbones; and those with mixed N, O, S and CH 2 Other skeletons of component parts.
[0159] Representative U.S. patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S. Patent Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,64,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5 ,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439, the entire contents of each of which are hereby incorporated herein by reference.
[0160] In other embodiments, suitable oligonucleotides include those in which the sugar and internucleoside bond (i.e., the backbone of the nucleotide unit) are replaced. The base unit is retained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound is a mimetic that has been shown to have excellent hybridization properties, referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar of the nucleoside is replaced by an amide-containing backbone (particularly an aminoethylglycine backbone). The nucleobase is retained and is directly or indirectly bound to the aza nitrogen atom of the backbone amide portion. Representative U.S. patents for teaching the preparation of PNA compounds include, but are not limited to, U.S. Patent Nos. 5,539,082; 5,714,331; and 5,719,262, the entire contents of each of which are hereby incorporated herein by reference. Additional PNA compounds suitable for use in the oligonucleotides of the present invention are described in, for example, Nielsen et al., Science, 1991, 254, 1497-1500.
[0161] Some embodiments particularly contemplated by the present invention include oligonucleotides having a phosphorothioate backbone and oligonucleotides having a heteroatom backbone, and the heteroatom backbone is particularly -CH 2 -NH-CH 2 -、-CH 2 -N(CH 3 )-O-CH 2 -[called methylene (methylimino) or MMI skeleton], -CH 2 -ON(CH 3 )-CH 2 -、-CH 2 -N(CH 3 )-N(CH 3 )-CH 2 - and -N(CH3 )-CH 2 -CH 2 -[where the natural phosphodiester backbone is represented by -OPO-CH 2 -], and the amide backbone of the above-mentioned U.S. Patent No. 5,602,240. In some embodiments, the oligonucleotides particularly contemplated herein have the morpholino backbone structure of the above-mentioned U.S. Patent No. 5,034,506. In other embodiments, the oligonucleotides described herein include phosphorodiamidate morpholino oligomers (PMOs) in which the deoxyribose moiety is replaced by a morpholine ring and the charged phosphodiester intersubunit bond is replaced by an uncharged phosphorodiamidate bond, as described in Summerton et al., Antisense Nucleic Acid Drug Dev. 1997, 7: 63-70.
[0162] Alternatively, nucleosides and nucleotides may also contain one or more substituted sugar moieties. Oligonucleotides (e.g., oligonucleotides) particularly contemplated herein may contain one of the following at the 2' position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S-, or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl, and alkynyl groups may be substituted or unsubstituted C 1 To C 10 Alkyl or C 2 To C 10 Exemplary suitable modifications include -O[(CH 2 ) n O] m CH 3 、-O(CH 2 ) n OCH 3 、-O(CH 2 ) n -NH 2 ,
[0163] -O(CH 2 ) n CH 3 、-O(CH 2 ) n -ONH 2 and -O(CH 2 ) n -ON[(CH 2 ) n CH 3 ] 2 , wherein n and m are from 1 to about 10. In other embodiments, the oligonucleotide comprises one of the following at the 2' position: C 1 To C 10Lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH 3 、OCN、Cl、Br、CN、CF 3 、OCF 3 、SOCH 3 、SO 2 CH 3 、ONO 2 、NO 2 、N 3 NH 2 , heterocycloalkyl, heterocycloalkylaryl, aminoalkylamino, polyalkylamino, substituted silyl, RNA cleavage group, reporter group, intercalator, group for improving the pharmacokinetic properties of oligonucleotides, or group for improving the pharmacodynamic properties of oligonucleotides, and other substituents with similar properties. In some embodiments, the modification includes 2'-methoxyethoxy (2'-O-CH 2 CH 2 OCH 3 , also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al., Helv. Chin. Acta, 1995, 78: 486-504), i.e., alkoxy-alkoxy. MOE nucleosides confer several beneficial properties to oligonucleotides compared to unmodified oligonucleotides, including, but not limited to, increased nuclease resistance, improved pharmacokinetic properties, reduced nonspecific protein binding, reduced toxicity, reduced immunostimulatory properties, and enhanced target affinity.
[0164] Another exemplary alternative contains a 2'-dimethylaminooxyethoxy group, i.e., -O(CH 2 ) 2 ON(CH 3 ) 2 The group, also known as 2'-DMAOE, as described in the Examples below, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-O-dimethylaminoethoxyethyl or 2'-DMAEOE), i.e., 2'-O-(CH 2 ) 2 -O-(CH 2 ) 2 -N(CH 3 ) 2 Further exemplary alternatives include: 5'-Me-2'-F nucleotides, 5'-Me-2'-OMe nucleotides, 5'-Me-2'-deoxynucleotides (both R and S isomers in these three families); 2'-alkoxyalkyls; and 2'-NMA (N-methylacetamide).
[0165] Other alternatives include 2'-methoxy (2'-OCH3 ), 2'-aminopropyloxy (2'-OCH 2 CH 2 CH 2 NH 2 ) and 2'-fluoro (2'-F). Similar modifications can also be made at other positions of the nucleosides and nucleotides of the oligonucleotide, particularly at the 3' position of the sugar on the 3' terminal nucleotide or in a 2'-5' linked oligonucleotide, and at the 5' position of the 5' terminal nucleotide. Oligonucleotides can also have sugar mimetics, such as a cyclobutyl moiety replacing the furanosyl sugar. Representative U.S. patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S. Patent Nos. 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; and 5,700,920, some of which are commonly owned by the present application. The entire contents of each of the foregoing are hereby incorporated herein by reference.
[0166] The oligonucleotides of the present invention may also include alternatives (e.g., modifications or substitutions) to nucleobases (commonly referred to in the art as "bases"). Unmodified or natural nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C), and uracil (U). Alternative nucleobases include other synthetic and natural nucleobases, such as 5-methylcytidine, 5-hydroxymethylcytidine, 5-formylcytidine, 5-carboxycytidine, pyrrolecytidine, dideoxycytidine, uridine, 5-methoxyuridine, 5-hydroxydeoxyuridine, dihydrouridine, 4-thiouridine, pseudouridine, 1-methyl-pseudouridine, deoxyuridine, 5-hydroxybutyne-2'-deoxyuridine, xanthine, isocyanate, 4-thiouridine ... Xanthine, 7-deazaxanthine, thienoguanine, 8-aza-7-deazaguanosine, 7-methylguanosine, 7-deazaguanosine, 6-aminomethyl-7-deazaguanosine, 8-aminoguanine, 2,2,7-trimethylguanosine, 8-methyladenine, 8-azidoadenine, 7-methyladenine, 7-deazaadenine, 3-deazaadenine, 2,6-diaminopurine, 2- Aminopurine, 7-deaza-8-azaadenine, 8-aminoadenine, thymine, dideoxythymine, 5-nitroindole, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouridine, 2-thiouridine and 2-thiouridine, 5-halouracil and cytosine, 5-propynyl uridine and cytidine, 6-azo uridine, cytidine and thymine, 4-thiouridine, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxy and other 8-substituted adenines and guanines, 5-halo, especially 5-bromo, 5-trifluoromethyl and other 5-substituted uridines and cytidines, 8-azaguanine and 8-azaadenine, and 3-deazaguanine.Further nucleobases include those disclosed in U.S. Pat. No. 3,687,808, those disclosed in Modified Nucleosides in Biochemistry, Biotechnology and Medicine, Herdewijn, P., ed. Wiley-VCH, 2008; those disclosed in The Concise Encyclopedia Of Polymer Science And Engineering, pp. 858-859, Kroschwitz, JL, ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., (1991) Angewandte Chemie, International Edition, 30: 613, and those disclosed by Sanghvi, Y S., Chapter 15, Antisense Research and Applications, pp. 289-302, Crooke, ST and Lebleu, B., eds., CRC Press, 1993. Some of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds to which the present invention is particularly directed. These nucleobases include 5-substituted pyrimidines, 6-azapyrimidines, and N-2, N-6, and 0-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil, and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, YS, Crooke, ST, and Lebleu, B., eds., Antisense Research and Applications, CRC Press, Boca Raton, 1993, pp. 276-278), and are exemplary base substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications.
[0167] Representative U.S. patents that teach the preparation of some of the alternative nucleobases mentioned above, as well as other alternative nucleobases, include, but are not limited to, the above-mentioned U.S. Patents Nos. 3,687,808; 4,845,205; 5,130,30; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; Nos. 5,594,121, 5,596,091; 5,614,617; 5,681,941; 5,750,692; 6,015,886; 6,147,200; 6,166,197; 6,222,025; 6,235,887; 6,380,368; 6,528,640; 6,639,062; 6,617,438; 7,045,610; 7,427,672; and 7,495,088, the entire contents of each of which are hereby incorporated by reference.
[0168] In other embodiments, the sugar moiety in the nucleotide can be a ribose molecule, optionally with a 2'-O-methyl, 2'-O-MOE, 2'-F, 2'-amino, 2'-O-propyl, 2'-aminopropyl or 2'-OH modification.
[0169] Oligonucleotides of the present invention may include one or more bicyclic sugar moieties." bicyclic sugar " is a furanose ring modified by the bridging of two atoms." bicyclic nucleoside " (" BNA ") is a nucleoside with a sugar moiety, and the sugar moiety includes a bridge connecting two carbon atoms of the sugar ring, thereby forming a bicyclic system. In certain embodiments, the bridge connects the 4'-carbon and 2'-carbon of the sugar ring. Therefore, in some embodiments, the reagent of the present invention may include one or more locked nucleosides. Locked nucleosides are nucleosides with modified ribose moieties, wherein the ribose moiety includes an extra bridge connecting 2' and 4' carbon. In other words, locked nucleosides are nucleosides comprising bicyclic sugar moieties, and the bicyclic sugar moieties include 4'-CH 2-O-2' bridge. This structure effectively "locks" the ribose in a 3'-endo structural conformation. Adding locked nucleosides to oligonucleotides has been shown to increase oligonucleotide stability in serum and reduce off-target effects (Grunweller, A. et al., (2003) Nucleic Acids Research 31(12): 3185-3193). Examples of bicyclic nucleosides for use in the polynucleotides of the present invention include, but are not limited to, nucleosides comprising a bridge between the 4' and 2' ribosyl ring atoms. In certain embodiments, the polynucleotide agents of the present invention comprise one or more bicyclic nucleosides comprising a 4' to 2' bridge. Examples of such 4' to 2' bridged bicyclic nucleosides include, but are not limited to, 4'-(CH 2 )-O-2'(LNA); 4'-(CH 2 )-S-2';4'-(CH 2 ) 2 -O-2'(ENA); 4'-CH(CH 3 )-O-2' (also called "constrained ethyl" or "cEt") and 4'-CH(CH 2 OCH 3 )-O-2' (and the like; see, e.g., U.S. Pat. No. 7,399,845); 4'-C(CH 3 )(CH 3 )-O-2' (and the like; see, e.g., U.S. Pat. No. 8,278,283); 4'-CH 2 -N(OCH 3 )-2' (and analogs thereof; see, e.g., U.S. Pat. No. 8,278,425); 4'-CH 2 -ON(CH 3 ) 2 -2' (see, e.g., U.S. Patent Publication No. 2004 / 0171570); 4'-CH 2 -N(R)-O-2', where R is H, C 1 -C 12 Alkyl or protecting group (see, for example, U.S. Pat. No. 7,427,672); 4'-CH 2 -C(H)(CH 3 )-2' (see, e.g., Chattopadhyaya et al., J. Org. Chem., 2009, 74, 118-134); and 4'-CH 2 -C(=CH 2 )-2' (and analogs thereof; see, eg, US Pat. No. 8,278,426). The entire contents of each of the foregoing are hereby incorporated herein by reference.
[0170] Other representative U.S. patents and U.S. patent publications that teach the preparation of locked nucleic acid nucleotides include, but are not limited to, the following: U.S. Patent Nos. 6,268,490; 6,525,191; 6,670,461; 6,770,748; 6,794,499; 6,998,484; 7,053,207; 7,034,133; 7,084,125; 7,399,845; 7,427,672; 7,569,686; 7,741,457; 8,022,193; 8,030,467; 8,278,425; 8,278,426; 8,278,283; US2008 / 0039618; and US2009 / 0012281, the entire contents of each of which are hereby incorporated herein by reference.
[0171] Any of the foregoing bicyclic nucleosides may be prepared with one or more stereochemical sugar configurations, including, for example, α-L-ribofuranose and β-D-ribofuranose (see WO 99 / 14226).
[0172] The oligonucleotides of the present invention may also be modified to include one or more constrained ethyl nucleosides. As used herein, "constrained ethyl nucleosides" or "cEt" are locked nucleosides that include a bicyclic sugar moiety that includes 4'-CH(CH 3 )-O-2' bridge. In one embodiment, the constrained ethyl nucleoside is in the S conformation, referred to herein as "S-cEt".
[0173] The oligonucleotides of the present invention may also contain one or more "conformationally restricted nucleosides" ("CRNs"). CRNs are nucleoside analogs whose linkers connect the C2' and C4' carbons of ribose or the C3 and C5' carbons of ribose. CRNs lock the ribose ring into a stable conformation and increase hybridization affinity to mRNA. The length of the linker is sufficient to place the oxygen in the optimal position for stability and affinity, thereby reducing ribose ring puckering.
[0174] Representative publications that teach the preparation of certain of the CRNs mentioned above include, but are not limited to, U.S. Patent Publication No. 2013 / 0190383; and PCT Publication No. WO 2013 / 036868, the entire contents of each of which are hereby incorporated by reference herein.
[0175] In some embodiments, the oligonucleotide of the present invention comprises one or more monomers as UNA (unlocking nucleoside) nucleoside. UNA is an unlocking acyclic nucleoside, in which any bond of sugar has been removed to form an unlocking "sugar" residue. In one example, UNA also comprises monomers from which the bond between C1'-C4' (i.e., the covalent carbon-oxygen-carbon bond between C1' and C4' carbon) has been removed. In another example, the C2'-C3' bond of sugar (i.e., the covalent carbon-carbon bond between C2' and C3' carbon) has been removed (see Nuc. Acids Symp. Series, 52, 133-134 (2008) and Fluiter et al., Mol. Biosyst., 2009, 10, 1039, incorporated herein by reference).
[0176] Representative US publications that teach the preparation of UNA include, but are not limited to, US Patent No. 8,314,227; and US Patent Publication Nos. 2013 / 0096289; 2013 / 0011922; and 2011 / 0313020, each of which is hereby incorporated by reference in its entirety.
[0177] The ribose molecule can also be modified with a cyclopropane ring to produce tricyclic deoxynucleic acid (tricyclic DNA). The ribose moiety can be replaced by another sugar, such as 1,5,-anhydrohexitol, threose (to produce threose nucleoside (TNA)) or arabinose (to produce arabinose nucleoside). The ribose molecule can also be replaced with a non-sugar, such as cyclohexene (to produce cyclohexene nucleoside) or ethylene glycol (to produce ethylene glycol nucleoside).
[0178] Potential stabilizing modifications at the termini of nucleoside molecules may include N-(acetylaminohexanoyl)-4-hydroxyprolinol (Hyp-C6-NHAc), N-(hexanoyl-4-hydroxyprolinol (Hyp-C6), N-(acetyl-4-hydroxyprolinol (Hyp-NHAc), thymidine-2'-O-deoxythymidine (ether), N-(aminohexanoyl)-4-hydroxyprolinol (Hyp-C6-amino), 2-docosahexyl-uridine-3"-phosphate, inverted base dT (idT), and the like. Disclosure of such modifications may be found in PCT Publication No. WO 2011 / 005861.
[0179] Other alternative chemistries for the oligonucleotides of the invention include a 5' phosphate or a 5' phosphate mimetic, such as a 5' terminal phosphate or phosphate mimetic of the oligonucleotide. Suitable phosphate mimetics are disclosed, for example, in US Patent Publication No. 2012 / 0157511, the entire contents of which are incorporated herein by reference.
[0180] Exemplary oligonucleotides of the present invention include nucleosides with alternative sugar moieties, and may also include DNA or RNA nucleosides. In some embodiments, oligonucleotides include: nucleosides including alternative sugar moieties, and DNA nucleosides. Alternative nucleosides are incorporated into the oligonucleotides of the present invention to enhance the affinity of the oligonucleotide to the target nucleic acid. In this case, alternative nucleosides may be referred to as alternative nucleotides of affinity enhancement.
[0181] In some embodiments, the oligonucleotide comprises at least 1 alternative nucleoside, such as at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15 or at least 16 alternative nucleosides. In other embodiments, the oligonucleotide comprises 1 to 10 alternative nucleosides, such as 2 to 9 alternative nucleosides, such as 3 to 8 alternative nucleosides, such as 4 to 7 alternative nucleosides, such as 6 or 7 alternative nucleosides. In an embodiment, the oligonucleotide of the present invention can include alternatives, which are independently selected from these three types of alternatives (alternative sugar moieties, alternative core bases and alternative nucleoside interkeys) or combinations thereof. Preferably, the oligonucleotide comprises one or more nucleosides comprising alternative sugar moieties, such as 2' sugar alternative nucleosides. In some embodiments, the oligonucleotides of the invention comprise one or more 2' sugar alternative nucleosides independently selected from 2'-O-alkyl-RNA, 2'-O-methyl-RNA, 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA, 2'-amino-DNA, 2'-fluoro-DNA, arabinose nucleic acid (ANA), 2'-fluoro-ANA and BNA (eg, LNA) nucleosides. In some embodiments, the one or more alternative nucleosides are BNA.
[0182] In some embodiments, at least one of the alternative nucleosides is a BNA (e.g., LNA), such as at least two of the alternative nucleosides, such as at least three, at least four, at least five, at least six, at least seven, or at least eight are BNAs. In still further embodiments, all alternative nucleosides are BNAs.
[0183] In further embodiments, the oligonucleotide comprises at least one alternative internucleoside bond. In some embodiments, the internucleoside bond in the continuous nucleotide sequence is a phosphorothioate or borophosphate internucleoside bond. In some embodiments, all internucleoside bonds in the continuous sequence of the oligonucleotide are phosphorothioate bonds. In some embodiments, the phosphorothioate bond is a stereochemically pure phosphorothioate bond. In some embodiments, the phosphorothioate bond is a Sp phosphorothioate bond. In other embodiments, the phosphorothioate bond is a Rp phosphorothioate bond.
[0184] In some embodiments, the oligonucleotide of the present invention comprises at least one alternative nucleoside as 2'-MOE-RNA, such as 2, 3, 4, 5, 6, 7, 8, 9 or 10 2'-MOE-RNA nucleoside units. In some embodiments, 2'-MOE-RNA nucleoside units are connected by thiophosphate bonds. In some embodiments, at least one of the alternative nucleoside is 2'-fluoro DNA, such as 2, 3, 4, 5, 6, 7, 8, 9 or 10 2'-fluoro-DNA nucleoside units. In some embodiments, the oligonucleotide of the present invention comprises at least one BNA unit and at least one 2' substituted modified nucleoside. In some embodiments of the present invention, the oligonucleotide comprises 2' sugar modified nucleosides and DNA units. In some embodiments, the oligonucleotide of the present invention or its continuous nucleotide region is a gapmer oligonucleotide.
[0185] Ligand-conjugated oligonucleotides
[0186] The oligonucleotides of the invention may be chemically linked to one or more ligands, moieties or conjugates that enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. Such moieties include, but are not limited to, lipid moieties, such as a cholesterol moiety (Letsinger et al., (1989) Proc. Natl. Acid. Sci. USA, 86:6553-6556), bile acid (Manoharan et al., (1994) Biorg. Med. Chem. Let., 4:1053-1060), thioethers (e.g., beryl-S-tritylthiol) (Manoharan et al., (1992) Ann. NY Acad. Sci., 660:306-309; Manoharan et al., (1993) Biorg. Med. Chem. Let., 3:2765-2770), thiol cholesterol (Oberhauser et al., (1992) Nucl. Acids Res., 20:533-538), a fatty chain (e.g., dodecanediol or undecyl residues) (Saison-Behmoaras et al., (1991) EMBO J, 10: 1111-1118; Kabanov et al., (1990) FEBS Lett., 259: 327-330; Svinarchuk et al., (1993) Biochimie, 75: 49-54), phospholipids (e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-phosphonate) (Manoharan et al., (1995) Tetrahedron Lett., 36: 3651-3654; Shea et al., (1990) Nucl. Acids Res., 18: 3777-3783), polyamines or polyethylene glycol chains (Manoharan et al., (1995) Nucleosides & Nucleotides, 14: 969-973), or adamantane acetic acid (Manoharan et al., (1995) Tetrahedron Lett., 36: 3651-3654), a palmityl moiety (Mishra et al., (1995) Biochim. Biophys. Acta, 1264: 229-237), or an octadecylamine or hexylamino-carbonyloxycholesterol moiety (Crooke et al., (1996) J. Pharmacol. Exp. Ther., 277: 923-937).
[0187] In one embodiment, a ligand alters the distribution, targeting, or lifetime of an oligonucleotide agent into which it is incorporated. In some embodiments, a ligand provides enhanced affinity (e.g., compared to a substance without such ligand) for a selected target (e.g., a molecule, a cell or cell type, a compartment, such as a cellular compartment or an organ compartment, a tissue, an organ, or a body region).
[0188] The ligand may include a naturally occurring substance, such as a protein (e.g., human serum albumin (HSA), low-density lipoprotein (LDL), or globulin); a carbohydrate (e.g., dextran, pullulan, chitin, chitosan, inulin, cyclodextrin, N-acetylglucosamine, N-acetylgalactosamine, or hyaluronic acid); or a lipid. The ligand may also be a recombinant molecule or a synthetic molecule, such as a synthetic polymer, such as a synthetic polyamino acid. Examples of polyamino acids include polyamino acids such as polylysine (PLL), poly-L-aspartic acid, poly-L-glutamic acid, styrene-maleic anhydride copolymer, poly-(L-lactide-co-ethanol ester) copolymer, divinyl ether-maleic anhydride copolymer, N-(2-hydroxypropyl) methacrylamide copolymer (HMPA), polyethylene glycol (PEG), polyvinyl alcohol (PVA), polyurethane, poly-(2-ethylacrylic acid), N-isopropylacrylamide polymer, or polyphosphazene. Examples of polyamines include polyethyleneimine, polylysine (PLL), spermine, spermidine, polyamines, pseudopeptide-polyamines, peptidomimetic polyamines, dendrimer polyamines, arginine, amidine, protamine, cationic lipids, cationic porphyrins, quaternary salts of polyamines, or α-helical peptides.
[0189] The ligand can also include a targeting group, such as a cell or tissue targeting agent, such as a lectin, a glycoprotein, a lipid or a protein, such as an antibody, which binds to a specific cell type, such as a kidney cell. The targeting group can be thyrotropin, melanocyte stimulating hormone, a lectin, a glycoprotein, a surfactant protein A, a mucin carbohydrate, a multivalent lactose, a multivalent galactose, N-acetyl-galactosamine, N-acetyl-glucosamine, a multivalent mannose, a multivalent fucose, a glycosylated polyamino acid, a multivalent galactose, transferrin, a bisphosphonate, polyglutamic acid, polyaspartic acid, a lipid, cholesterol, a steroid, bile acid, folic acid, vitamin B12, vitamin A, biotin, or an RGD peptide or RGD peptide mimetic.
[0190] Other examples of ligands include dyes, intercalating agents (e.g., acridine), cross-linkers (e.g., psoralen, mitomycin C), porphyrins (TPPC4, texaphyrin, Sapphyrin), polycyclic aromatic hydrocarbons (e.g., phenazine, dihydrophenazine), artificial endonucleases (e.g., EDTA), lipophilic molecules (e.g., cholesterol, cholic acid, adamantaneacetic acid, 1-pyrenebutyric acid, dihydrotestosterone, 1,3-bis-O(hexadecyl)glycerol, geranyloxyhexyl, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl, palmitic acid, myristic acid, O3-(oleoyl)lithocholic acid, O3-(oleoyl)cholenic acid, dimethoxytrityl or phenoxazine) and peptide conjugates (e.g., antennapedia peptide, Tat peptide), alkylating agents, phosphates, amino groups, sulfhydryl groups, PEG (e.g., PEG-40K), MPEG, [MPEG] 2 , polyamino, alkyl, substituted alkyl, radioactive markers, enzymes, haptens (e.g., biotin), transport / absorption enhancers (e.g., aspirin, vitamin E, folic acid), synthetic ribonucleases (e.g., imidazole, bisimidazole, histamine, imidazole clusters, acridine-imidazole conjugates, Eu3+ complexes of tetraazamacrocycles), dinitrophenyl, HRP or AP.
[0191] The ligand can be a protein (e.g., a glycoprotein) or a peptide (e.g., a molecule with a specific affinity for a co-ligand) or an antibody (e.g., an antibody that binds to a specific cell type (e.g., a hepatocyte). The ligand can also include hormones and hormone receptors. They can also include non-peptide substances such as lipids, lectins, carbohydrates, vitamins, cofactors, multivalent lactose, multivalent galactose, N-acetyl-galactosamine, N-acetyl-galactosamine, multivalent mannose, or multivalent fucose.
[0192] The ligand can be a substance (e.g., a drug) that can increase the uptake of the oligonucleotide agent into the cell, for example, by disrupting the cytoskeleton of the cell, for example, by disrupting the microtubules, microfilaments, and / or intermediate filaments of the cell. The drug can be, for example, taxon, vincristine, vinblastine, cytochalasin, nocodazole, japlakinolide, latrunculin A, phalloidin, swinholide A, indanocine, or myoservin.
[0193] In some embodiments, the ligand connected to the oligonucleotide as described herein is used as a pharmacokinetic regulator (PK regulator). PK regulators include lipophilic groups, bile acids, steroids, phospholipid analogs, peptides, protein binders, PEG, vitamins, etc. Exemplary PK regulators include, but are not limited to, cholesterol, fatty acids, cholic acid, lithocholic acid, dialkyl glycerides, diacylglycerides, phospholipids, sphingolipids, naproxen, ibuprofen, vitamin E, biotin, etc. It is also known that oligonucleotides containing many thiophosphate bonds bind to serum proteins, so short oligonucleotides (e.g., oligonucleotides containing multiple thiophosphate bonds in the backbone) are also tested as ligands (e.g., as PK regulating ligands) for the present invention. In addition, aptamers that bind serum components (e.g., serum proteins) are also suitable for use as PK regulating ligands in the embodiments described herein.
[0194] The ligand-conjugated oligonucleotides of the invention can be synthesized by using oligonucleotides with pendant reactive functional groups, such as those derived from attaching a linker molecule to an oligonucleotide (described below). Such reactive oligonucleotides can be reacted directly with commercially available ligands, synthetic ligands with any of a variety of protecting groups, or ligands having a linking moiety attached thereto.
[0195] The oligonucleotides used in the conjugates of the present invention can be conveniently and routinely prepared by well-known solid phase synthesis techniques. Equipment for such synthesis is sold by several suppliers, including, for example, Applied Biosystems (Foster City, Calif.). Any other means known in the art for such synthesis may be additionally or alternatively employed. It is also known that other oligonucleotides are prepared using similar techniques, such as phosphorothioates and alkylated derivatives.
[0196] In the ligand-conjugated oligonucleotides of the present invention (e.g., sequence-specifically linked nucleosides with ligand molecules of the present invention), oligonucleotides and oligonucleosides can be assembled on a suitable DNA synthesizer using standard nucleotide or nucleoside precursors, or nucleotide or nucleoside conjugate precursors that already carry a linking portion, ligand-nucleotide or nucleoside-conjugate precursors that already carry a ligand molecule, or non-nucleoside building blocks with a ligand.
[0197] When a conjugate precursor that already carries a linking moiety is used, the synthesis of a sequence-specific linked nucleoside is typically completed, and the ligand molecule is then reacted with the linking moiety to form a ligand-conjugated oligonucleotide. In some embodiments, the oligonucleotides or linked nucleosides of the invention are synthesized by an automated synthesizer, using phosphoramidites derived from ligand-nucleoside conjugates in addition to standard phosphoramidites and non-standard phosphoramidites that are commercially available and routinely used for oligonucleotide synthesis.
[0198] Lipid conjugates
[0199] In one embodiment, the ligand or conjugate is a lipid or lipid-based molecule. Such lipid or lipid-based molecules preferably bind serum proteins, such as human serum albumin (HSA). Ligands that bind to HSA allow the conjugate to be distributed to target tissues, such as non-renal target tissues of the body. Lipids or lipid-based ligands can (a) increase tolerance to degradation of the conjugate, (b) increase targeting or transport to target cells or cell membranes, and / or (c) can be used to regulate binding to serum proteins (e.g., HSA).
[0200] In another aspect, the ligand is a moiety, such as a vitamin, that is taken up by a target cell (e.g., a proliferating cell). Exemplary vitamins include vitamins A, E, and K.
[0201] Cell Permeabilization Agents
[0202] On the other hand, the ligand is a cell permeating agent, preferably a helical cell permeating agent. Preferably, the agent is amphipathic. Exemplary agents are peptides, such as tat or antennapedia. If the agent is a peptide, it can be modified, including peptidyl mimetics, invertomers, non-peptide or pseudopeptide bonds, and the use of D-amino acids. The helical agent is preferably an alpha-helical agent, which preferably has a lipophilic phase and a lipophobic phase.
[0203] The ligand can be a peptide or peptidomimetic. Peptidomimetic (also referred to herein as oligopeptidomimetic) is a molecule that can be folded into a determined three-dimensional structure similar to a natural peptide. The combination of peptides and peptidomimetic with oligonucleotide reagents can affect the pharmacokinetic distribution of oligonucleotides, such as by enhancing cell recognition and absorption. The peptide or peptidomimetic portion can be about 5-50 amino acids long, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 amino acids long.
[0204] The peptide or peptidomimetic can be, for example, a cell penetrating peptide, a cationic peptide, an amphipathic peptide or a hydrophobic peptide (e.g., mainly composed of Tyr, Trp or Phe). The peptide portion can be a dendritic peptide, a constrained peptide or a cross-linked peptide. In another alternative, the peptide portion can include a hydrophobic membrane translocation sequence (MTS). An exemplary peptide containing a hydrophobic MTS is RFGF with the amino acid sequence AAVALLPAVLLALLAP. An RFGF analog containing a hydrophobic MTS (e.g., the amino acid sequence AALLPVLLAAP) can also be a targeting portion. The peptide portion can be a "delivery" peptide that can carry large polar molecules (including peptides, oligonucleotides and proteins) through the cell membrane. For example, it has been found that the sequence from HIV Tat protein (GRKKRRQRRRPPQ) and the sequence from Drosophila antennapedia protein (RQIKIWFQNRRMKWKK) can act as a delivery peptide. The peptide or peptidomimetic can be encoded by a random sequence of DNA, such as a peptide identified from a phage display library or a one-bead-one-compound (OBOC) combinatorial library (Lam et al., Nature, 354: 82-84, 1991). An example of a peptide or peptidomimetic tethered to an oligonucleotide agent by an incorporated monomer unit for cell targeting purposes is an arginine-glycine-aspartic acid (RGD)-peptide, or an RGD mimetic. The length of the peptide portion can range from about 5 amino acids to about 40 amino acids. The peptide portion can have structural modifications, such as to increase stability or direct conformational properties. Any of the structural modifications described below can be used.
[0205] The RGD peptides used in the compositions and methods of the invention can be linear or cyclic and can be modified (e.g., glycosylated or methylated) to facilitate targeting to specific tissues. Peptides and peptidomimetics containing RGD can contain D-amino acids, as well as synthetic RGD mimetics. In addition to RGD, other parts of targeting integrin ligands can also be used. Some conjugates of this ligand target PECAM-1 or VEGF.
[0206] Cell penetrating peptides are capable of penetrating cells, such as microbial cells, such as bacterial or fungal cells, or mammalian cells, such as human cells. Microbial cell penetrating peptides can be, for example, alpha helical linear peptides (e.g., LL-37 or Ceropin P1), peptides containing disulfide bonds (e.g., alpha-defensins, beta-defensins or bactenecins), or peptides containing only one or two main amino acids (e.g., PR-39 or indolicidin). Cell penetrating peptides can also contain a nuclear localization signal (NLS). For example, a cell penetrating peptide can be an amphipathic peptide consisting of two parts, such as MPG, which is derived from the fusion peptide domain of HIV-1 gp41 and the NLS of the large T antigen of SV40 (Simeoni et al., Nucl. Acids Res. 31: 2717-2724, 2003).
[0207] Carbohydrate conjugates
[0208] In some embodiments of the compositions and methods of the present invention, the oligonucleotide further comprises a carbohydrate. As described herein, carbohydrate-conjugated oligonucleotides are conducive to the in vivo delivery of nucleic acids and compositions suitable for in vivo therapeutic use. As used herein, "carbohydrate" refers to a compound that is itself a carbohydrate composed of one or more monosaccharide units (which may be linear, branched or cyclic) with at least 6 carbon atoms, wherein oxygen, nitrogen or sulfur atoms are bonded to each carbon atom; or a compound having a carbohydrate moiety as a part thereof, wherein the carbohydrate moiety is composed of one or more monosaccharide units (which may be linear, branched or cyclic) each having at least six carbon atoms, and oxygen, nitrogen or sulfur atoms are bonded to each carbon atom. Representative carbohydrates include sugars (monosaccharides, disaccharides, trisaccharides, and oligosaccharides containing about 4, 5, 6, 7, 8 or 9 monosaccharide units) and polysaccharides (such as starch, glycogen, cellulose and polysaccharide gum). Specific monosaccharides include sugars of C5 and above (eg, C5, C6, C7, or C8); disaccharides and trisaccharides include sugars having two or three monosaccharide units (eg, C5, C6, C7, or C8).
[0209] In one embodiment, the carbohydrate conjugates used in the compositions and methods of the invention are monosaccharides.
[0210] In some embodiments, the carbohydrate conjugate further comprises one or more additional ligands as described above, such as, but not limited to, a PK modifier and / or a cell penetrating peptide.
[0211] Additional carbohydrate conjugates (and linkers) suitable for use in the present invention include those described in PCT Publication Nos. WO 2014 / 179620 and WO 2014 / 179627 (each of which is incorporated herein by reference in its entirety).
[0212] Connectors
[0213] In some embodiments, the conjugates or ligands described herein can be linked to oligonucleotides with various linkers, which can be cleavable or non-cleavable.
[0214] Linkers typically contain direct bonds or atoms (such as oxygen or sulfur), units (such as NR 8 , C(O), C(O)NH, SO, SO 2 、SO 2 NH) or a chain of atoms such as, but not limited to, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocycloalkyl, heterocycloalkenyl, heterocycloalkynyl, aryl, heteroaryl, heterocyclo, cycloalkyl, cycloalkenyl, alkylarylalkyl, alkylarylalkenyl, alkylarylalkynyl, alkenylalkylaryl, alkenylarylalkenyl, alkenylarylalkynyl, alkynylarylalkyl, alkynylarylalkenyl, alkynylarylalkynyl, alkylheteroarylalkyl, alkyl heteroarylalkenyl, alkylheteroarylalkynyl, alkenylheteroarylalkyl, alkenylheteroarylalkenyl, alkenylheteroarylalkynyl, alkynylheteroarylalkyl, alkynylheteroarylalkenyl, alkynylheteroarylalkynyl, alkylheterocycloalkyl, alkylheterocycloalkenyl, alkylheterocycloalkynyl, alkenylheterocycloalkyl, alkenylheterocycloalkenyl, alkenylheterocycloalkynyl, alkynylheterocycloalkyl, alkynylheterocycloalkenyl, alkynylheterocycloalkynyl, alkylaryl, alkenylaryl, alkynylaryl, alkylheteroaryl, alkenylheteroaryl, alkynylheteroaryl, wherein one or more methylene groups may be replaced by O, S, S(O), SO 2 、N(R 8 ), C(O), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic group blocking or terminating; wherein R 8 is hydrogen, acyl, aliphatic or substituted aliphatic. In one embodiment, the linker is between about 1-24 atoms, 2-24, 3-24, 4-24, 5-24, 6-24, 6-18, 7-18, 8-18 atoms, 7-17, 8-17, 6-16, 7-17 or 8-16 atoms.
[0215] A cleavable linking group is a group that is sufficiently stable outside the cell, but is cleaved upon entry into the target cell to release the two parts of the linker that are held together. In a preferred embodiment, the cleavable linking group is at least about 10 times, 20 times, 30 times, 40 times, 50 times, 60 times, 70 times, 80 times, 90 times or more, or at least about 100 times faster in the target cell or under a first reference condition (which can, for example, be selected to simulate or represent intracellular conditions) than in the blood of the subject or under a second reference condition (which can, for example, be selected to simulate or represent conditions found in blood or serum).
[0216] Cleavable linking groups are susceptible to the effects of cleavage agents, such as pH, redox potential, or the presence of degrading molecules. Generally, cleavage agents are more prevalent or have higher levels or activity in cells than in serum or blood. Examples of such degrading agents include: redox agents that are selective for a particular substrate or have no substrate specificity, including, for example, oxidases or reductases or reducing agents (such as thiols) present in cells, which can degrade redox cleavable linking groups by reduction; esterases; endosomes or agents that can produce an acidic environment, such as those that result in a pH of five or less; enzymes that can hydrolyze or degrade acid cleavable linking groups by acting as generalized acids, peptidases (which can be substrate specific), and phosphatases.
[0217] Cleavable bond groups (such as disulfide bonds) can be easily affected by pH. The pH of human serum is 7.4, while the average intracellular pH is slightly lower, ranging from about 7.1-7.3. Endosomes have a more acidic pH, in the range of 5.5-6.0, while lysosomes have an even more acidic pH, about 5.0. Some linkers will have a cleavable linking group that is cleaved at a preferred pH to release the cationic lipid from the intracellular ligand or to a desired compartment of the cell.
[0218] The linker can comprise a cleavable linking group that can be cleaved by a specific enzyme. The type of cleavable linking group incorporated into the linker can depend on the cell to be targeted. For example, a liver targeting ligand can be linked to a cationic lipid via a linker comprising an ester group. Hepatocytes are rich in esterases, so the linker will be more effectively cleaved in hepatocytes than in cell types that are not rich in esterases. Other cell types rich in esterases include cells of the lung, kidney cortex, and testis.
[0219] When targeting cell types rich in peptidases, such as hepatocytes and synoviocytes, linkers containing peptide bonds can be used.
[0220] Generally, the suitability of a candidate cleavable linking group can be assessed by testing the ability of a degradation agent (or condition) to cut a candidate linking group. It will also be desirable to test the ability of a candidate cleavable linking group to tolerate cutting in blood or when in contact with other non-target tissues. Therefore, the relative sensitivity to cutting between the first condition and the second condition can be determined, wherein the first condition is selected to indicate cutting in target cells, and the second condition is selected to indicate cutting in other tissues or biological fluids (such as blood or serum). It can be assessed in a cell-free system, cell, cell culture, organ or tissue culture or whole animal. A preliminary assessment is performed under cell-free or culture conditions, and it can be useful to confirm by further evaluating in whole animals. In a preferred embodiment, compared with blood or serum (or under in vitro conditions selected to simulate extracellular conditions), the cutting of a useful candidate compound in a cell (or under in vitro conditions selected to simulate intracellular conditions) is at least about 2, 4, 10, 20, 30, 40, 50, 60, 70, 80, 90 or about 100 times faster.
[0221] Redox cleavable linker
[0222] In one embodiment, the cleavable linking group is a redox cleavable linking group that is cleaved when reduced or oxidized. An example of a reductive cleavable linking group is a disulfide linking group (--S--S--). In order to determine whether a candidate cleavable linking group is a suitable "reductive cleavable linking group", or for example, suitable for use with a specific oligonucleotide moiety and a specific targeting agent, the method described herein can be viewed. For example, candidates can be evaluated by incubating with dithiothreitol (DTT) or other reducing agents, using reagents known in the art, which simulate the cleavage rate observed in cells (such as target cells). Candidates can also be evaluated under conditions selected to simulate blood or serum conditions. In one embodiment, candidate compounds are cut up to about 10% in blood. In other embodiments, compared with blood (or under in vitro conditions selected to simulate extracellular conditions), useful candidate compounds are degraded in cells (or under in vitro conditions selected to simulate intracellular conditions) at least about 2, 4, 10, 20, 30, 40, 50, 60, 70, 80, 90 or about 100 times faster. Standard enzyme kinetic assays can be used to determine the rate of cleavage of candidate compounds under conditions selected to mimic intracellular media and compared to conditions selected to mimic extracellular media.
[0223] Phosphate-based cleavable linker
[0224] In another embodiment, the cleavable linker includes a phosphate-based cleavable linking group. The phosphate-based cleavable linking group is cleaved by an agent that degrades or hydrolyzes the phosphate group. An example of an agent that cleaves the phosphate group in a cell is an enzyme in the cell, such as a phosphatase. An example of a phosphate-based linking group is -OP(O)(OR k )-O-、-OP(S)(OR k )-O-、-OP(S)(SR k )-O-、-SP(O)(OR k )-O-、-OP(O)(OR k )-S-、-SP(O)(OR k )-S-、-OP(S)(OR k )-S-、-SP(S)(OR k )-O-、-OP(O)(R k )-O-、-OP(S)(R k )-O-、-SP(O)(R k )-O-、-SP(S)(R k )-O-、-SP(O)(R k )-S-、-OP(S)(R k )-S-. Similar methods as described above can be used to evaluate these candidates.
[0225] Acid cleavable linker
[0226] In another embodiment, the cleavable linker includes an acidic cleavable linking group. An acidic cleavable linking group is a linking group that is cleaved under acidic conditions. In a preferred embodiment, the acidic cleavable linking group is cleaved in an acidic environment with a pH of about 6.5 or less (e.g., about 6.0, 5.75, 5.5, 5.25, 5.0 or less), or is cleaved by a reagent (such as an enzyme that can be used as a broad acid). In cells, specific low pH organelles (such as endosomes and lysosomes) can provide a cleavage environment for the acidic cleavable linking group. Examples of acidic cleavable linking groups include, but are not limited to, hydrazones, esters, and esters of amino acids. The acidic cleavable group may have the general formula –C=NN--, C(O)O, or --OC(O). A preferred embodiment is when the carbon connected to the oxygen (alkoxy) of the ester is an aryl, substituted alkyl, or tertiary alkyl (such as dimethylpentyl or tert-butyl). Similar methods to those described above can be used to evaluate these candidates.
[0227] Ester-based linking groups
[0228] In another embodiment, the cleavable linker includes an ester-based cleavable linking group. The ester-based cleavable linking group is cut by enzymes (such as esterases and amidases) in the cell. Examples of ester-based cleavable linking groups include, but are not limited to, esters of alkylene, alkenylene, and alkynylene. The ester-cleavable linking group has the general formula -- C (O) O -- or -- OC (O) --. Similar methods as described above can be used to evaluate these candidates.
[0229] Peptide-based cleavage groups
[0230] In yet another embodiment, the cleavable linker comprises a peptide-based cleavable linking group. Peptide-based cleavable linking groups are cleaved by enzymes in the cell (such as peptidases and proteases). Peptide-based cleavable linking groups are peptide bonds formed between amino acids to produce oligopeptides (e.g., dipeptides, tripeptides, etc.) and polypeptides. Peptide-based cleavable groups do not include amide groups (-C(O)NH-). Amide groups can be formed between any alkylene, alkenylene, or alkynylene groups. Peptide bonds are a special type of amide bond formed between amino acids to produce peptides and proteins. Peptide-based cleavage groups are generally limited to peptide bonds (i.e., amide bonds) formed between amino acids, which produce peptides and proteins, and do not include the entire amide functional group. Peptide-based cleavable linking groups have the general formula
[0231] -NHCHR A C(O)NHCHR B C(O)--, where R A and R B are the R groups of two adjacent amino acids. These candidates can be evaluated using methods similar to those described above.
[0232] In one embodiment, the oligonucleotide of the present invention is conjugated to a carbohydrate via a linker. Linkers include divalent and trivalent branched linker groups. Linkers for oligonucleotide carbohydrate conjugates include, but are not limited to, those described in Formulas 24-35 of PCT Publication No. WO2018 / 195165.
[0233] Representative U.S. patents that teach the preparation of oligonucleotide conjugates include, but are not limited to, U.S. Patent Nos. 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5, 486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,83 0; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241; 5,391,723; 5,416,203; 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,56 Nos. 7,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941; 6,294,664; 6,320,017; 6,576,752; 6,783,931; 6,900,297; 7,037,646; 8,106,022, the entire contents of each of which are hereby incorporated by reference.
[0234] It is not necessary to uniformly modify all positions in a given compound, and in fact, more than one of the above modifications can be incorporated into a single compound, or even into a single nucleoside within an oligonucleotide. The present invention also includes oligonucleotide compounds that are chimeric compounds. Chimeric oligonucleotides generally contain at least one region in which RNA is modified to confer increased tolerance to nuclease degradation, increased cellular uptake, and / or increased binding affinity to the target nucleic acid on the oligonucleotide. Another region of the oligonucleotide can serve as a substrate for an enzyme capable of cutting RNA: DNA. As an example, ribonuclease H is a cellular endonuclease that cuts the RNA strand of an RNA: DNA duplex. Therefore, activation of ribonuclease H results in cutting of the RNA target, thereby greatly enhancing the efficiency of the oligonucleotide in inhibiting gene expression. Therefore, when using chimeric oligonucleotides, comparable results can generally be obtained with shorter oligonucleotides compared to phosphorothioate deoxy oligonucleotides hybridized to the same target region. Cutting of the RNA target can be routinely detected by gel electrophoresis and (if necessary) related nucleic acid hybridization techniques known in the art.
[0235] In some cases, the nucleotides of an oligonucleotide may be modified with non-ligand groups. Many non-ligand molecules have been conjugated to oligonucleotides in order to enhance the activity, cellular distribution or cellular uptake of the oligonucleotides, and procedures for performing such conjugations are available in the scientific literature. Such non-ligand moieties include lipid moieties such as cholesterol (Kubo, T. et al., Biochem. Biophys. Res. Comm, 2007, 365(1):54-61; Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86:6553), cholic acid (Manoharan et al., Bioorg. Med. Chem. Lett., 1994, 4:1053), thioethers (e.g., hexyl-S-tritylthiol) (Manoharan et al., Ann. NY Acad. Sci., 1992, 660:306; Manoharan et al., Bioorg. Med. Chem. Let., 1993, 3:2765), thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20: 533), fatty chains (e.g., dodecandiol or undecyl residues) (Saison-Behmoaras et al., EMBO J., 1991, 10: 111; Kabanov et al., FEBS Lett., 1990, 259: 327; Svinarchuk et al., Biochimie, 1993, 75: 49), phospholipids (e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate) (Manoharan et al., Tetrahedron Lett., 1995, 36: 3651; Shea et al., Nucl. Acids Res., 1990, 18: 3777), polyamine or polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14: 969), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36: 3651), palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264: 229), or octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277: 923). Representative U.S. patents that teach the preparation of such oligonucleotide conjugates have been listed above. The typical conjugation scheme involves synthesizing an oligonucleotide with an amino linker at one or more positions in the sequence. The amino group is then reacted with the molecule to be conjugated using an appropriate coupling or activating agent.The conjugation reaction can be carried out while the oligonucleotide is still bound to a solid support, or in solution phase after cleavage of the oligonucleotide. Purification of the oligonucleotide conjugate by HPLC will generally provide a pure conjugate.
[0236] Drug Use
[0237] The oligonucleotide compositions described herein can be used in the methods of the invention and, while not being bound by theory, are believed to exert their desired effects through their ability to modulate the level, state and / or activity of PCDH19, e.g., by inhibiting the activity or level of PCDH19 protein in mammalian cells.
[0238] One aspect of the present invention relates to a method for treating PCDH19-related disorders (e.g., epilepsy, schizophrenia, and autism) in a subject in need thereof. Another aspect of the present invention includes reducing (e.g., reducing by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97%, 99%, or 100%) PCDH19 levels in cells identified as subjects with PCDH19-related disorders. Yet another aspect includes a method for inhibiting PCDH19 expression in subject cells. The method may include contacting cells with oligonucleotides, the amount of which effectively inhibits the expression of PCDH19 in cells, thereby inhibiting the expression of PCDH19 in cells.
[0239] Based on the above methods, further aspects of the invention include oligonucleotides of the invention, or compositions comprising such oligonucleotides, for use in therapy, or as drugs, or for treating PCDH19-related disorders in subjects in need, or for reducing PCDH19 levels in cells of subjects identified as suffering from PCDH19-related disorders, or for inhibiting the expression of PCDH19 in subject cells. Uses include contacting cells with oligonucleotides in an amount that effectively inhibits the expression of PCDH19 in cells, thereby inhibiting the expression of PCDH19 in cells. The embodiments described below in connection with the methods of the invention also apply to these further aspects.
[0240] Cells can be contacted with oligonucleotides in vitro or in vivo. Contacting cells with oligonucleotides in vivo includes contacting cells or cell populations within a subject (e.g., a human subject) with an oligonucleotide. Combinations of in vitro and in vivo methods of contacting cells are also possible. As discussed above, contacting cells can be direct or indirect. In addition, contacting cells can be accomplished by targeting ligands, including any ligands described herein or known in the art. In some embodiments, the targeting ligand is a carbohydrate moiety, such as GalNAc 3The ligand, or any other ligand that directs the oligonucleotide to the site of interest. The cells may include those of the central nervous system or muscle cells.
[0241] Inhibiting the expression of the PCDH19 gene includes any level of inhibition of the PCDH19 gene, such as at least partial inhibition of PCDH19 gene expression, such as inhibition of at least about 20%. In certain embodiments, inhibition is at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99%.
[0242] Inhibiting the expression of PCDH19 gene includes inhibiting the expression of WT allele, mutant allele or its combination. For example, the subject can have a mutation (e.g., nonsense, missense and / or frameshift mutation) in one allele of PCDH19 gene. Since the gene is X-linked, female subjects are heterozygous, while male subjects are hemizygous (another copy is inactivated). Oligonucleotides can selectively target mutant alleles. Oligonucleotides can selectively target WT alleles. Oligonucleotides can target two alleles.
[0243] The expression of the PCDH19 gene can be assessed based on the level of any variable associated with PCDH19 gene expression, such as PCDH19 mRNA levels or PCDH19 protein levels.
[0244] Inhibition can be assessed by a reduction in the absolute or relative level of one or more of these variables compared to a control level. A control level can be any type of control level used in the art, such as a pre-dose baseline level, or a level determined from a similar subject, cell or sample that is untreated or treated with a control (e.g., a buffer only control or an inactive agent control).
[0245] In certain embodiments, surrogate markers can be used to detect inhibition of PCDH19. For example, effective treatment of a PCDH19-related disorder with an agent that reduces PCDH19 expression can be understood to indicate a clinically relevant reduction in PCDH19, as indicated by acceptable diagnostic and monitoring criteria.
[0246] In some embodiments of the methods of the invention, the expression of the PCDH19 gene is inhibited by at least 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95%, or is inhibited to below the detection level of the assay. In certain embodiments, the methods include clinically relevant inhibition of PCDH19 expression, for example, as indicated by clinically relevant results after treating a subject with an agent to reduce PCDH19 expression.
[0247] Inhibition of PCDH19 gene expression can be manifested as a reduction in the amount of mRNA expressed by a first cell or cell population (such cells can be present, for example, in a sample derived from a subject) compared to a second cell or cell population that is substantially identical to the first cell or cell population but has not been treated as such (control cells that have not been treated with an oligonucleotide or have not been treated with an oligonucleotide targeting a gene of interest), wherein the PCDH19 gene is transcribed in the first cell or cell population and has been treated (for example, by contacting the cell with an oligonucleotide of the invention, or by administering an oligonucleotide of the invention to a subject in which the cell is or has been present) such that expression of the PCDH19 gene is inhibited. The degree of inhibition can be expressed in the following manner:
[0248]
[0249] In other embodiments, inhibition of PCDH19 gene expression can be assessed by a reduction in a parameter functionally associated with PCDH19 gene expression (e.g., PCDH19 protein expression or PCDH19 activity). PCDH19 gene silencing can be determined in any cell expressing PCDH19 (endogenous or heterologous from an expression construct) by any assay known in the art.
[0250] The inhibition of PCDH19 protein expression can be manifested as a reduction in the PCDH19 protein level (e.g., the protein level expressed in a sample derived from a subject) expressed by a cell or cell group. As explained above, for the assessment of mRNA inhibition, the inhibition of protein expression levels in treated cells or cell groups can be similarly expressed as a percentage of protein levels in control cells or cell groups.
[0251] Control cells or cell groups that can be used to evaluate the inhibition of PCDH19 gene expression include cells or cell groups that have not yet been contacted with the oligonucleotides of the present invention. For example, control cells or cell groups can be derived from a single subject (e.g., a human or animal subject) and then treated with oligonucleotides.
[0252] Any method known in the art for evaluating mRNA expression can be used to determine the level of PCDH19 mRNA expressed by a cell or cell population. In one embodiment, the expression level of PCDH19 in a sample is determined by detecting a transcribed polynucleotide or a portion thereof (e.g., mRNA of a PCDH19 gene). RNA can be extracted from cells using RNA extraction techniques, including, for example, extraction using acid phenol / guanidine isothiocyanate (RNAzol B; Biogenesis), RNEASY TM RNA preparation kit (Qiagen) or PAXgene (PreAnalytix, Switzerland). Typical assay formats using RNA hybridization include nuclear run-on assays, RT-PCR, ribonuclease protection assays, northern blots, in situ hybridization, and microarray analysis. The method described in PCT Publication WO2012 / 177906 (the entire contents of which are incorporated herein by reference) can be used to detect circulating PCDH19 mRNA. In some embodiments, nucleic acid probes are used to determine the expression level of PCDH19. As used herein, the term "probe" refers to any molecule that can selectively bind to a specific PCDH19 sequence (e.g., to an mRNA or polypeptide). The probe can be synthesized by a person skilled in the art, or derived from an appropriate biological preparation. The probe can be specifically designed to be labeled. Examples of molecules that can be used as probes include, but are not limited to, RNA, DNA, proteins, antibodies, and organic molecules.
[0253] The isolated mRNA can be used for hybridization or amplification assays, including but not limited to Southern analysis or northern analysis, polymerase chain reaction (PCR) analysis and probe arrays. A method for determining mRNA levels involves contacting the isolated mRNA with a nucleic acid molecule (probe), which can hybridize with PCDH19 mRNA. In one embodiment, the mRNA is fixed on a solid surface and contacted with the probe, such as by running the isolated mRNA on an agarose gel and transferring the mRNA from the gel to a membrane (such as nitrocellulose). In an alternative embodiment, the probe is fixed on a solid surface, and the mRNA is contacted with the probe, such as in an AFFYMETRIX gene chip array. Technicians can easily make known mRNA detection methods suitable for determining the level of PCDH19 mRNA.
[0254] Alternative methods for determining the expression level of PCDH19 in a sample involve processes such as nucleic acid amplification and / or reverse transcriptase (to prepare cDNA) of mRNA in the sample, such as by RT-PCR (experimental embodiments are set forth in Mullis, 1987, U.S. Pat. No. 4,683,202), ligase chain reaction (Barany (1991) Proc. Natl. Acad. Sci. USA 88:189-193), self-sustaining sequence replication (Guatelli et al. (1990) Proc. Natl. Acad. Sci. USA 87:1874-1878), transcription amplification system (Kwoh et al. (1989) Proc. Natl. Acad. Sci. USA 86:1173-1177), Q-β replicase (Lizardi et al. (1988) Bio / Technology 6:1197), rolling circle replication (Lizardi et al., U.S. Pat. No. 5,854,033), or any other nucleic acid amplification method, followed by detection of the amplified molecules using techniques well known to those skilled in the art. These detection schemes are particularly useful for detecting nucleic acid molecules if they are present in very small numbers. In a specific aspect of the invention, quantitative fluorescent RT-PCR (i.e., TAQMAN TM system) or DUAL- Luciferase assay was used to determine the expression level of PCDH19.
[0255] The expression level of PCDH19 mRNA can be monitored using membrane blotting (such as used in hybridization analysis, such as northern blotting, Southern blotting, dot blotting, etc.) or microwells, sample tubes, gels, beads or fibers (or any solid support containing bound nucleic acids). See U.S. Patents Nos. 5,770,722; 5,874,219; 5,744,305; 5,677,195; and 5,445,934, which are incorporated herein by reference. The determination of PCDH19 expression levels can also include the use of nucleic acid probes in solution.
[0256] In some embodiments, branched DNA (bDNA) determination or real-time PCR (qPCR) is used to assess mRNA expression levels. The use of this PCR method is described and illustrated in the examples presented herein. Such methods can also be used to detect PCDH19 nucleic acids.
[0257] Any method known in the art for measuring protein levels can be used to determine the level of PCDH19 protein expression. Such methods include, for example, electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), super diffusion chromatography, fluid or gel precipitation reaction, absorption spectrum, colorimetric determination, spectrophotometry, flow cytometry, immunodiffusion (unidirectional or bidirectional), immunoelectrophoresis, protein blotting, radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), immunofluorescence assay, electrochemiluminescence assay, etc. Such assays can also be used to detect proteins indicating the presence or replication of PCDH19 proteins.
[0258] In some embodiments of the methods of the present invention, the oligonucleotide is administered to the subject so that the oligonucleotide is delivered to a specific site in the subject. The inhibition of PCDH19 expression can be assessed by measuring the level or level change of PCDH19 mRNA or PCDH19 protein in a sample derived from a specific site in the subject. In certain embodiments, the method includes clinically relevant inhibition of PCDH19 expression, for example, as indicated by clinically relevant results after treating the subject with an agent to reduce PCDH19 expression.
[0259] In other embodiments, the amount and duration of administration of the oligonucleotide is effective to result in a reduction (e.g., a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%) of one or more symptoms of a PCDH19-related disorder. Such symptoms include, but are not limited to, prolonged seizures, frequent seizures, behavioral and developmental delays, movement and balance problems, orthopedic conditions, language and speech delay problems, growth and nutrition problems, sleep difficulties, chronic infections, sensory integration disorders, autonomic nervous system disorders, and sweating.
[0260] Compared to an untreated subject population, treating a PCDH19-related disorder can result in an increase in the average survival time of an individual or subject population treated according to the present invention. For example, the survival time of an individual or the average survival time of a population increases by more than 30 days (more than 60 days, 90 days, or 120 days). The increase in individual survival time or the increase in the average survival time of a population can be measured in any reproducible manner. The increase in individual survival time can be measured, for example, by calculating the length of survival time after an individual begins treatment with a compound described herein. The increase in the average survival time of a population can be measured, for example, by calculating the length of survival time after an individual completes the first round of treatment with a compound described herein or a pharmaceutically acceptable salt of the compound. The increase in the average survival time of a population can also be measured, for example, by calculating the average length of survival time after a population completes the first round of treatment with a compound described herein or a pharmaceutically acceptable salt of the compound.
[0261] Treatment of PCDH19-related disorders can also result in a reduction in the mortality rate of the treated subject population compared to an untreated population. For example, the mortality rate is reduced by more than 2% (e.g., more than 5%, 10%, or 25%). The reduction in the mortality rate of the treated subject population can be measured in any reproducible manner, such as by calculating the average number of disease-related deaths per unit time after the population begins treatment with a compound described herein or a pharmaceutically acceptable salt of the compound. The reduction in the mortality rate of the population can also be measured, for example, by calculating the average number of disease-related deaths per unit time after the population completes the first round of treatment with a compound described herein or a pharmaceutically acceptable salt of the compound.
[0262] Oligonucleotide delivery
[0263] The delivery of the oligonucleotides of the present invention to cells, such as cells in a subject (such as a human subject, such as a subject in need, such as a subject suffering from a PCDH19 related disorder) can be achieved in a variety of different ways. For example, delivery can be carried out by contacting the cell with the oligonucleotides of the present invention in vitro or in vivo. It is also possible to directly deliver in vivo by applying a composition comprising the oligonucleotides to the subject. These alternatives are discussed further below.
[0264] Generally, any method of delivering nucleic acid molecules (in vitro or in vivo) can be applied to the oligonucleotides of the present invention (see, e.g., Akhtar S. and Julian R L., (1992) Trends Cell. Biol. 2(5): 139-144 and WO94 / 02595, which are incorporated herein by reference in their entirety). For in vivo delivery, factors to be considered for delivery of oligonucleotide molecules include, for example, the biological stability of the delivered molecule, the prevention of nonspecific effects, and the accumulation of the delivered molecule in the target tissue. The nonspecific effects of oligonucleotides can be minimized by local administration, such as by direct injection or implantation into a tissue or a localized formulation. Local administration to the treatment site maximizes the local concentration of the agent, limits exposure of the agent to systemic tissues that may otherwise be damaged by the agent or that may degrade the agent, and allows a lower total dose of the oligonucleotide molecule to be administered.
[0265] For systemic administration of oligonucleotides to treat diseases, oligonucleotides can include alternative core bases, alternative sugar moieties and / or alternative internucleoside bonds, or alternative delivery using a drug delivery system; both methods prevent oligonucleotides from being rapidly degraded by endonucleases and exonucleases in vivo. The modification of oligonucleotides or drug carriers can also allow oligonucleotide compositions to be targeted to target tissues, and avoid undesirable off-target effects. Oligonucleotide molecules can be modified by chemical conjugation with lipophilic groups (such as cholesterol) to enhance cell uptake and prevent degradation. In alternative embodiments, drug delivery systems can be used to deliver oligonucleotides, such as nanoparticles, lipid nanoparticles, polymer nanoparticles, lipid complex nanoparticles, dendrimers, polymers, liposomes or cationic delivery systems. Positively charged cationic delivery systems promote the combination of oligonucleotide molecules (negatively charged), and enhance the interaction on negatively charged cell membranes to allow cells to effectively take in oligonucleotides. Cationic lipids, dendrimers or polymers can be combined with oligonucleotides, or induced to form vesicles or micelles that package oligonucleotides. When administered systemically, the formation of vesicles or micelles further prevents degradation of the oligonucleotide. Generally, any nucleic acid delivery method known in the art can be applied to the delivery of the oligonucleotides of the present invention. Methods for making and administering cationic oligonucleotide complexes are well within the capabilities of those skilled in the art (see, e.g., Sorensen, DR, et al. (2003) J. Mol. Biol 327: 761-766; Verma, U N. et al. (2003) Clin. Cancer Res. 9: 1291-1300; Arnold, AS et al. (2007) J. Hypertens. 25: 197-205, which are incorporated herein by reference in their entirety).Some non-limiting examples of drug delivery systems that can be used for systemic delivery of oligonucleotides include DOTAP (Sorensen, D R., et al. (2003), supra; Verma, U N. et al., (2003), supra), Oligofectamine, "solid nucleic acid lipid particles" (Zimmermann, T S. et al., (2006) Nature 441: 111-114), cardiolipin (Chien, P Y. et al., (2005) Cancer Gene Ther. 12: 321-328; Pal, A. et al., (2005) Int J. Oncol. 26: 1087-1091), polyethyleneimine (Bonnet M et al., (2006) Nature 441: 111-114), poly(vinylpyrrolidone) (Poly ... E. et al., (2008) Pharm. Res. August 16, electronically published ahead of print; Aigner, A. (2006) J. Biomed. Biotechnol. 71659), Arg-Gly-Asp (RGD) peptides (Liu, S. (2006) Mol. Pharm. 3: 472-487) and polyamidoamines (Tomalia, D. A. et al., (2007) Biochem. Soc. Trans. 35: 61-67; Yoo, H. et al., (1999) Pharm. Res. 16: 1799-1804). In some embodiments, the oligonucleotides are complexed with cyclodextrins for systemic administration. Methods of administration and pharmaceutical compositions of oligonucleotides and cyclodextrins can be found in U.S. Pat. No. 7,427,605, which is incorporated herein by reference in its entirety. In some embodiments, the oligonucleotides of the present invention are delivered by polymer nanoparticles or lipid complex nanoparticles. Methods of administration and pharmaceutical compositions of oligonucleotide and polymer nanoparticles and lipid complex nanoparticles can be found in U.S. patents.
[0266] Application Nos. 2017 / 0121454; 2016 / 0369269; 2016 / 0279256; 2016 / 0251478; 2016 / 0230189; 2015 / 0335764; 2015 / 0307554; 2015 / 0174549; 2014 / 0342003; 2014 / 0135376; and 2013 / 0317086, which are incorporated herein by reference in their entirety.
[0267] Membrane Molecular Assembly Delivery Method
[0268] A variety of membranous molecular assembly delivery methods can also be used to deliver the oligonucleotides of the present invention, including polymers known in the art, biodegradable microparticles or microcapsule delivery devices. For example, colloidal dispersion systems can be used for targeted delivery of oligonucleotide agents described herein. Colloidal dispersion systems include macromolecular complexes, nanocapsules, microspheres, beads and lipid-based systems, including oil-in-water emulsions, micelles, mixed micelles and liposomes. Liposomes are artificial membrane vesicles that can be used as delivery vehicles in vitro and in vivo. Large unilamellar vesicles (LUVs) with a size range of 0.2-4.0 μm have been shown to encapsulate a considerable percentage of aqueous buffer containing macromolecules. Liposomes can be used to transfer and deliver active ingredients to the site of action. Since the liposome membrane is similar to a biological membrane in structure, when the liposome is applied to a tissue, the liposome bilayer fuses with the bilayer of the cell membrane. As the liposome and cell fusion progress, the internal water content including the oligonucleotide is delivered to the cell, where the oligonucleotide can specifically bind to the target RNA and can mediate ribonuclease H-mediated gene silencing. In some cases, liposomes are also specifically targeted, for example, oligonucleotides are directed to specific cell types. The composition of liposomes is generally a combination of phospholipids, usually in combination with steroids (especially cholesterol). Other phospholipids or other lipids may also be used. The physical characteristics of liposomes depend on the presence of pH, ionic strength and divalent cations.
[0269] Liposomes containing oligonucleotides can be prepared by a variety of methods. In one example, the lipid component of the liposome is dissolved in a detergent so that micelles are formed with the lipid component. For example, the lipid component can be an amphipathic cationic lipid or a lipid conjugate. The detergent can have a very high critical micelle concentration and can be nonionic. Exemplary detergents include cholate, CHAPS, octyl glucoside, deoxycholate, and lauroyl sarcosine. The oligonucleotide preparation is then added to the micelle containing the lipid component. The cationic groups on the lipid interact with the oligonucleotide and condense around the oligonucleotide to form liposomes. After condensation, the detergent is removed, for example, by dialysis to produce a liposome preparation of the oligonucleotide.
[0270] If necessary, a carrier compound that aids condensation can be added during the condensation reaction, for example by controlled addition. For example, the carrier compound can be a polymer other than nucleic acid (e.g., spermine or spermidine). The pH can also be adjusted to facilitate condensation.
[0271] Methods for producing stable polynucleotide delivery vectors that incorporate polynucleotide / cationic lipid complexes as structural components of the delivery vector are further described, for example, in WO 96 / 37194, the entire contents of which are incorporated herein by reference. Liposome formation may also include one or more aspects of the exemplary methods described in Feigner, PL et al., (1987) Proc. Natl. Acad. Sci. USA 8:7413-7417; U.S. Pat. No. 4,897,355; U.S. Pat. No. 5,171,678; Bangham et al., (1965) M. Mol. Biol. 23:238; Olson et al., (1979) Biochim. Biophys. Acta 557:9; Szoka et al., (1978) Proc. Natl. Acad. Sci. 75:4194; Mayhew et al., (1984) Biochim. Biophys. Acta 775:169; Kim et al., (1983) Biochim. Biophys. Acta 728:339; and Fukunaga et al., (1984) Endocrinol. 115:757. Common techniques for preparing lipid aggregates of appropriate size for use as delivery vehicles include sonication and freeze-thaw plus extrusion (see, e.g., Mayer et al., (1986) Biochim. Biophys. Acta 858:161). When consistently small (50 to 200 nm) and relatively uniform aggregates are desired, microfluidization can be used (Mayhew et al., (1984) Biochim. Biophys. Acta 775:169). These methods are readily adapted for packaging oligonucleotide formulations into liposomes.
[0272] Liposomes are divided into two major categories. Cationic liposomes are positively charged liposomes that interact with negatively charged nucleic acid molecules to form stable complexes. The positively charged nucleic acid / liposome complex binds to the negatively charged cell surface and is internalized in the endosome. Due to the acidic pH within the endosome, the liposomes rupture, releasing their contents into the cytoplasm (Wang et al. (1987) Biochem. Biophys. Res. Commun., 147: 980-985).
[0273] Liposomes are pH sensitive or negatively charged, capturing nucleic acids rather than complexing with them. Since both nucleic acids and lipids are similarly charged, repulsion occurs rather than complex formation. Nevertheless, some nucleic acids are trapped within the aqueous interior of these liposomes. pH sensitive liposomes have been used to deliver nucleic acids encoding thymidine kinase genes to cell monolayers in culture. Expression of exogenous genes was detected in target cells (Zhou et al. (1992) Journal of Controlled Release, 19: 269-274).
[0274] A major type of liposome composition comprises phospholipids other than natural source phosphatidylcholine. Neutral liposome compositions can be formed, for example, by dimyristoylphosphatidylcholine (DMPC) or dipalmitoylphosphatidylcholine (DPPC). Anionic liposome compositions are generally formed by dimyristoylphosphatidylglycerol, while anionic fusogenic liposomes are mainly formed by dioleoylphosphatidylethanolamine (DOPE). Another type of liposome composition is formed by phosphatidylcholine (PC), such as soybean PC and egg PC. Another type is formed by a mixture of phospholipids and / or phosphatidylcholine and / or cholesterol.
[0275] Examples of other methods for introducing liposomes into cells in vitro and in vivo include U.S. Pat. No. 5,283,185; U.S. Pat. No. 5,171,678; WO 94 / 00569; WO 93 / 24640; WO 91 / 16024; Feigner, (1994) J. Biol. Chem. 269:2550; Nabel, (1993) Proc. Natl. Acad. Sci. 90:11307; Nabel, (1992) Human Gene Ther. 3:649; Gershon, (1993) Biochem. 32:7143; and Strauss, (1992) EMBO J. 11:417.
[0276] Nonionic liposomal systems have also been examined to determine their utility for delivering drugs to the skin, particularly systems containing nonionic surfactants and cholesterol. TM I (glyceryl dilaurate / cholesterol / polyoxyethylene-10-stearyl ether) and NOVASOME TM A nonionic liposome formulation of II (glyceryl distearate / cholesterol / polyoxyethylene-10-stearyl ether) was used to deliver cyclosporin A to the dermis of mouse skin. The results showed that this nonionic liposome system effectively promoted the deposition of cyclosporin A into different layers of the skin (Hu et al., (1994) STP Pharma. Sci., 4(6): 466).
[0277] The liposomes may also be sterically stabilized liposomes comprising one or more specialized lipids that result in increased circulation life relative to liposomes lacking such specialized lipids. Examples of sterically stabilized liposomes are those in which a portion (A) of the vesicle-forming lipid portion of the liposome comprises one or more glycolipids, such as monosialoganglioside G M1 , or (B) derivatized with one or more hydrophilic polymers, such as polyethylene glycol (PEG) moieties. While not wishing to be bound by any particular theory, it is believed in the art that, at least for sterically stabilized liposomes containing gangliosides, sphingomyelin, or PEG-derivatized lipids, the increased circulation half-life of these sterically stabilized liposomes is derived from a reduced uptake into cells by the reticuloendothelial system (RES) (Allen et al., (1987) FEBS Letters, 223: 42; Wu et al., (1993) Cancer Research, 53: 3765).
[0278] Various liposomes comprising one or more glycolipids are known in the art. Papahadjopoulos et al. (Ann. NY Acad. Sci., (1987), 507:64) reported monosialoganglioside G M1 , galactosylceraeroside sulfate and phosphatidylinositol improve the blood half-life of liposomes. Gabizon et al. (Proc. Natl. Acad. Sci. USA, (1988), 85: 6949) described these findings. U.S. Patent No. 4,837,028 and WO 88 / 04924 (both to Allen et al.) disclose liposomes comprising (1) sphingomyelin and (2) ganglioside G M1 or galactocerebroside sulfate. U.S. Patent No. 5,543,152 (Webb et al.) discloses liposomes comprising sphingomyelin. Liposomes comprising 1,2-sn-dimyristoylphosphatidylcholine are disclosed in WO 97 / 13499 (Lim et al.).
[0279] In one embodiment, cationic liposomes are used. Cationic liposomes have the advantage of being able to fuse with cell membranes. Although non-cationic liposomes cannot fuse with plasma membranes as effectively, they are taken up by macrophages in vivo and can be used to deliver oligonucleotides to macrophages.
[0280] Further advantages of liposomes include: liposomes obtained from natural phospholipids are biocompatible and biodegradable; liposomes can incorporate a variety of water-soluble and lipid-soluble drugs; liposomes can protect oligonucleotides encapsulated in their internal compartments from metabolism and degradation (Rosoff, "Pharmaceutical Dosage Forms," Lieberman, Rieger and Banker (eds.), 1988, Vol. 1, p. 245). Important considerations in preparing liposome formulations are lipid surface charge, vesicle size, and the water volume of the liposomes.
[0281] The positively charged synthetic cationic lipid N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA) can be used to form small liposomes that spontaneously interact with nucleic acids to form lipid-nucleic acid complexes that are capable of fusing with negatively charged lipids of the cell membrane of tissue culture cells, resulting in the delivery of oligonucleotides (see, e.g., Feigner, PL et al., (1987) Proc. Natl. Acad. Sci. USA 8:7413-7417 and U.S. Pat. No. 4,897,355 for a description of DOTMA and its use with DNA).
[0282] The DOTMA analog 1,2-bis(oleoyloxy)-3-(trimethylamino)propane (DOTAP) can be used in combination with phospholipids to form DNA complex vesicles. TM (Bethesda Research Laboratories, Gaithersburg, Md.) is an effective agent for delivering highly anionic nucleic acids to living tissue culture cells, comprising positively charged DOTMA liposomes, which spontaneously interact with negatively charged polynucleotides to form complexes. When sufficient positively charged liposomes are used, the net charge on the resulting complex is also positive. The positively charged complex prepared in this way spontaneously connects to the negatively charged cell surface, fuses with the plasma membrane, and effectively delivers functional nucleic acids to, for example, tissue culture cells. Another commercially available cationic lipid 1,2-bis(oleoyloxy)-3,3-(trimethylamino)propane ("DOTAP") (Boehringer Mannheim, Indianapolis, Ind.) is different from DOTMA in that the oleoyl moiety is connected by an ester, rather than by an ether bond.
[0283] Other reported cationic lipid compounds include those that have been conjugated to a variety of moieties, including, for example, carboxyspermine that has been conjugated to one of two types of lipids, and include compounds such as 5-carboxysperminylglycine dioctanoylamide ("DOGS") (TRANSFECTAM TM , Promega, Madison, Wis.) and dipalmitoylphosphatidylethanolamine 5-carboxyspermyl-amide ("DPPES") (see, e.g., U.S. Pat. No. 5,171,678).
[0284] Another cationic lipid conjugate includes derivatization of lipids with cholesterol ("DC-Chol"), which has been formulated into liposomes in combination with DOPE (see Gao, X. and Huang, L., (1991) Biochim. Biophys. Res. Commun. 179: 280). Lipopolylysine, made by conjugating polylysine to DOPE, is reported to be effective in transfection in the presence of serum (Zhou, X. et al., (1991) Biochim. Biophys. Acta 1065: 8). For certain cell lines, these liposomes containing conjugated cationic lipids are believed to have lower toxicity than compositions containing DOTMA and provide more effective transfection. Other commercially available cationic lipid products include DMRIE and DMRIE-HP (Vical, La Jolla, Calif.) and Lipofectamine (DOSPA) (Life Technology, Inc., Gaithersburg, Md.). Other cationic lipids suitable for delivery of oligonucleotides are described in WO 98 / 39359 and WO 96 / 37194.
[0285] Liposomal formulations are particularly suitable for topical administration, and liposomes have several advantages over other formulations. Such advantages include reduced side effects associated with high systemic absorption of the administered drug, increased accumulation of the administered drug at the desired target, and the ability to administer the oligonucleotide to the skin. In some embodiments, liposomes are used to deliver oligonucleotides to epidermal cells and also enhance the penetration of oligonucleotides into dermal tissues, such as the skin. For example, liposomes can be applied topically. Topical delivery of drugs formulated into liposomes to the skin has been documented (see, e.g., Weiner et al., (1992) Journal of Drug Targeting, vol. 2, 405-410 and du Plessis et al., (1992) Antiviral Research, 18: 259-265; Mannino, RJ and Fould-Fogerite, S., (1998) Biotechniques 6: 682-690; Itani, T. et al., (1987) Gene 56:267-276; Nicolau, C. et al. (1987) Meth. Enzymol. 149:157-176; Straubinger, RM and Papahadjopoulos, D. (1983) Meth. Enzymol. 101:512-527; Wang, CY and Huang, L., (1987) Proc. Natl. Acad. Sci. USA 84:7851-7855).
[0286] Nonionic liposome systems were also examined to determine their effectiveness in delivering drugs to the skin, particularly systems containing nonionic surfactants and cholesterol. Nonionic liposome formulations containing NOVASOME I (glyceryl dilaurate / cholesterol / polyoxyethylene-10-stearyl ether) and NOVASOME II (glyceryl distearate / cholesterol / polyoxyethylene-10-stearyl ether) were used to deliver drugs to the dermis of mouse skin. Such formulations containing oligonucleotides can be used to treat skin disorders.
[0287] The targeting of liposomes is also possible and known in the art based on, for example, organ-specific, cell-specific and organelle-specific. In the case of liposome targeted delivery systems, lipid groups can be incorporated into the lipid bilayer of the liposome to maintain the stable combination of the targeting ligand and the liposome bilayer. Various linking groups can be used to connect lipid chains to the targeting ligand. Other methods are known in the art and are described in, for example, U.S. Patent Application Publication No. 20060058255, whose linking groups are incorporated herein by reference.
[0288] Liposomes containing oligonucleotides can be made highly deformable. This deformability can enable liposomes to penetrate holes smaller than the average radius of liposomes. For example, transfersomes are another type of liposomes and are highly deformable lipid aggregates that are attractive candidates for drug delivery vehicles. Transfersomes can be described as lipid droplets, which have a high degree of deformability so that they can easily penetrate holes smaller than droplets. Transfersomes can be prepared by adding surface edge activators (surface edge activators, usually surfactants) to standard liposome compositions. Transfersomes containing oligonucleotides can be delivered, for example, by infecting subcutaneous delivery, so that oligonucleotides are delivered to keratinocytes in the skin. In order to pass through intact mammalian skin, lipid vesicles must pass through a series of pores under the influence of a suitable transdermal gradient, with a diameter of each pore less than 50nm. In addition, due to lipid properties, these transfersomes can be self-optimized (suitable for the shape of pores, such as in the skin), self-repairing, and can frequently reach their targets without fragmentation, and are usually self-loaded. Transfersomes have been used to deliver serum albumin to the skin. Transfersome-mediated delivery of serum albumin has been shown to be as effective as subcutaneous injection of a solution containing serum albumin.
[0289] Other formulations amenable to testing for the present invention are described in U.S. Provisional Application Nos. 61 / 018,616, filed January 2, 2008; 61 / 018,611, filed January 2, 2008; 61 / 039,748, filed March 26, 2008; 61 / 047,087, filed April 22, 2008; and 61 / 051,528, filed May 8, 2008. PCT Application No. PCT / US2007 / 080331, filed October 3, 2007, also describes formulations amenable to testing for the present invention.
[0290] Surfactants are widely used in formulations such as emulsions (including microemulsions) and liposomes. The most common method for classifying and ranking the properties of many different types of surfactants (natural and synthetic) is by using the hydrophile / lipophile balance (HLB). The nature of the hydrophilic group (also called the "head") provides the most useful way to classify the different surfactants used in formulations (Rieger, Pharmaceutical Dosage Forms, Marcel Dekker, Inc., New York, NY, 1988, p. 285).
[0291] If the surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants are widely used in pharmaceuticals and cosmetics and are available in a wide range of pH values. Generally, their HLB values range from 2 to about 18, depending on their structure. Nonionic surfactants include nonionic esters such as ethylene glycol esters, propylene glycol esters, glycerol esters, polyglycerol esters, sorbitol esters, sucrose esters and ethoxylated esters. Nonionic alkanolamides and ethers (such as fatty alcohol ethoxylates, propoxylated alcohols and ethoxylated / propoxylated block polymers) are also included in this category. Polyoxyethylene surfactants are the most popular members of the nonionic surfactant classification.
[0292] If the surfactant molecule carries a negative charge when dissolved or dispersed in water, the surfactant is classified as anionic. Anionic surfactants include carboxylates (such as soaps), acyl lactylates, acyl amides of amino acids, esters of sulfuric acid (such as alkyl sulfates and ethoxylated alkyl sulfates), sulfonates (such as alkylbenzene sulfonates, acyl isethionates, acyl taurates and sulfosuccinates), and phosphates. The most important members of the anionic surfactant classification are alkyl sulfates and soaps.
[0293] If the surfactant molecule carries a positive charge when dissolved or dispersed in water, the surfactant is classified as a cationic surfactant. Cationic surfactants include quaternary ammonium salts and ethoxylated amines. Quaternary ammonium salts are the most commonly used members of this classification.
[0294] If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is classified as an amphoteric surfactant. Amphoteric surfactants include acrylic acid derivatives, substituted alkyl amides, N-alkyl betaines, and phospholipids.
[0295] The use of surfactants in drug products, formulations, and emulsions has been reviewed (Rieger, Pharmaceutical Dosage Forms, Marcel Dekker, Inc., New York, NY, 1988, p. 285).
[0296] Oligonucleotides for use in the methods of the invention can also be provided as micellar formulations. Micelles are a specific type of molecular assembly in which amphiphilic molecules are arranged in a spherical structure so that the hydrophobic portions of all molecules face inward, so that the hydrophilic portions are in contact with the surrounding water. If the environment is hydrophobic, the opposite arrangement exists.
[0297] Lipid nanoparticle-based delivery methods
[0298] Oligonucleotide of the present invention can be encapsulated in lipid formulations completely, such as lipid nanoparticles (LNP) or other nucleic acid-lipid particles. LNP is extremely useful for systemic applications, because they show the circulation life of extension after intravenous (iv) injection, and accumulate at distal positions (such as the position physically separated from the application site). LNP comprises " pSPLP ", and it comprises encapsulation condensing agent-nucleic acid complex listed as PCT publication No. WO 00 / 03683. Particle of the present invention typically has an average diameter of about 50nm to about 150nm, more typically about 60nm to about 130nm, more typically about 70nm to about 110nm, most typically about 70nm to about 90nm, and is substantially nontoxic. In addition, when present in nucleic acid-lipid particles of the present invention, nucleic acid tolerates nuclease degradation in aqueous solution. Nucleic acid-lipid particles and methods for making them are disclosed in, for example, U.S. Patent Nos. 5,976,567; 5,981,501; 6,534,484; 6,586,410; 6,815,432; U.S. Publication No. 2010 / 0324120 and PCT Publication No. WO 96 / 40964.
[0299] In one embodiment, the lipid-drug ratio (mass / mass ratio) (e.g., lipid-oligonucleotide ratio) will be in the range of about 1: 1 to about 50: 1, about 1: 1 to about 25: 1, about 3: 1 to about 15: 1, about 4: 1 to about 10: 1, about 5: 1 to about 9: 1, or about 6: 1 to about 9: 1. Ranges between the above ranges are also considered part of the invention.
[0300] Non-limiting examples of cationic lipids include N,N-dioleyl-N,N-dimethylammonium chloride (DODAC), N,N-distearyl-N,N-dimethylammonium bromide (DDAB), N--(1-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTAP), N--(1-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTMA), N,N-dimethyl-2,3-dioleyloxy)propylamine (DODMA), 1,2-dilinoleoyloxy-N,N-dimethylaminopropane (DLinDMA), 1,2-dialinolenoyloxy-N,N-dimethylaminopropane (DLenDMA), and N-(1-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTMA). A), 1,2-dilinoleoylaminoformyloxy-3-dimethylaminopropane (DLin-C-DAP), 1,2-dilinoleoyloxy-3-(dimethylamino)acetoxypropane (DLin-DAC), 1,2-dilinoleoyloxy-3-morpholinylpropane (DLin-MA), 1,2-dilinoleoyl-3-dimethylaminopropane (DLinDAP), 1,2-dilinoleoylthio-3-dimethylaminopropane (DLin-S-DMA), 1-linoleoyl-2-linoleoyloxy-3-dimethylaminopropane (DLin-2-DMAP), 1,2-dilinoleoyloxy-3-trimethylaminopropane chloride (DLin-TMA.Cl) , 1,2-dilinoleoyl-3-trimethylaminopropane chloride (DLin-TAP.Cl), 1,2-dilinoleoyloxy-3-(N-methylpiperazinyl)propane (DLin-MPZ), or 3-(N,N-dilinoleoylamino)-1,2-propanediol (DLinAP), 3-(N,N-dioleoylamino)-1,2-propanediol (DOAP), 1,2-dilinoleoyloxy-3-(2-N,N-dimethylamino)ethoxypropane (DLin-EG-DMA), 1,2-dilinolenoyloxy-N,N-dimethylaminopropane (DLinDMA), 2,2-dilinoleoyl-4-dimethylaminomethyl-[1,3]-dioxolane ( DLin-K-DMA) or its analogs, (3aR,5s,6aS)-N,N-dimethyl-2,2-di((9Z,12Z)-octadecane-9,12-dienyltetrahydro--3aH-cyclopenta[d][1,3]dioxol-5-amine (ALN100), (6Z,9Z,28Z,31Z)-heptatriacontane-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butyrate (MC3), 1,1'-(2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-ylethylazadiyldocosan-2-ol (Tech G1) or mixtures thereof. The cationic lipid may comprise, for example, from about 20 mol% to about 50 mol% or about 40 mol% of the total lipid present in the particle.
[0301] The ionizable / non-cationic lipid can be an anionic lipid or a neutral lipid, including, but not limited to, distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoylphosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoylphosphatidylethanolamine (POPE), dioleoylphosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (DOPE-mal), dipalmitoylphosphatidylethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), distearoylphosphatidylethanolamine (DSPE), 16-O-monomethyl PE, 16-O-dimethyl PE, 18-1-trans PE, 1-stearoyl-2-oleoylphosphatidylethanolamine (SOPE), cholesterol, or mixtures thereof. The non-cationic lipid can be, for example, about 5 mol % to about 90 mol %, about 10 mol %, or about 60 mol % (if cholesterol is included) of the total lipid present in the particle.
[0302] The conjugated lipid that inhibits particle aggregation can be, for example, polyethylene glycol (PEG)-lipids, including but not limited to PEG-diacylglycerol (DAG), PEG-dialkoxypropyl (DAA), PEG-phospholipids, PEG-ceramide (Cer), or mixtures thereof. The PEG-DAA conjugate can be, for example, PEG-dilauroyloxypropyl (Cer). 12 ), PEG-dimyristoyloxypropyl (C 14 ), PEG-dipalmitoyloxypropyl (C 16 ) or PEG-distearoyloxypropyl (C 18 ). The conjugated lipid that prevents aggregation of the particles can be, for example, 0 mol % to about 20 mol % or about 2 mol % of the total lipid present in the particles.
[0303] In some embodiments, the nucleic acid-lipid particle further comprises cholesterol, for example, at about 10 mol % to about 60 mol % or about 50 mol % of the total lipid present in the particle.
[0304] Combination therapy
[0305] The methods of the present invention can be used alone or in combination with additional therapeutic agents (e.g., other agents for treating PCDH19-related disorders or symptoms associated therewith), or in combination with other types of therapies to treat PCDH19-related disorders. In combination therapy, the dose of one or more therapeutic compounds can be reduced from the standard dose when administered alone. For example, the dose can be determined empirically by drug combination and arrangement, or can be inferred by isoradiometric analysis (e.g., Black et al., Neurology 65: S3-S6 (2005)). In this case, the dose of the compound should provide a therapeutic effect when combined.
[0306] In some embodiments, the oligonucleotide reagents described herein can be used in combination with additional therapeutic agents to treat PCDH19-related disorders. In some embodiments, the additional therapeutic agent can be an oligonucleotide (eg, ASO) that hybridizes to the mRNA of a gene associated with a PCDH19-related disorder.
[0307] In some embodiments, the second therapeutic agent is a chemotherapeutic agent (eg, a cytotoxic agent or other compound useful for treating a PCDH19-related disorder).
[0308] In some embodiments, the second therapeutic agent is an anti-epileptic agent.
[0309] The second agent can be a therapeutic agent that is a non-drug treatment. For example, the second therapeutic agent is physical therapy.
[0310] In any combination embodiment described herein, the first therapeutic agent and the second therapeutic agent can be administered simultaneously or sequentially (in either order). The first therapeutic agent can be administered immediately, at most 1 hour, at most 2 hours, at most 3 hours, at most 4 hours, at most 5 hours, at most 6 hours, at most 7 hours, at most 8 hours, at most 9 hours, at most 10 hours, at most 11 hours, at most 12 hours, at most 13 hours, 14 hours, at most 16 hours, at most 17 hours, at most 18 hours, at most 19 hours, at most 20 hours, at most 21 hours, at most 22 hours, at most 23 hours, at most 24 hours, or at most 1-7 days, 1-14 days, 1-21 days, or 1-30 days before or after the second therapeutic agent.
[0311] Pharmaceutical composition
[0312] The oligonucleotides described herein are preferably formulated as pharmaceutical compositions for administration to human subjects in a biologically compatible form suitable for in vivo administration.
[0313] The compounds described herein can be used in the form of free alkali, in the form of salts, solvates, and as prodrugs. All forms are within the scope of the methods described herein. According to the method of the present invention, as will be appreciated by those skilled in the art, the described compound or its salt, solvate or prodrug can be applied to the subject in various forms according to the selected route of administration. The compounds described herein can be applied, for example, by oral, parenteral, intrathecal, intraventricular, intracerebral parenchyma, intrabuccal, sublingual, nasal, rectal, patch, pump or transdermal administration and corresponding formulated pharmaceutical compositions. Parenteral administration includes intravenous, intraperitoneal, subcutaneous, intramuscular, transepithelial, nasal, intrapulmonary, intrathecal, intraventricular, intracerebral parenchyma, rectal and topical administration. Parenteral administration can be carried out by continuous infusion in the selected time period.
[0314] The compounds described herein can be administered at any stage of life. The compounds can be administered to newborns, neonates, infants, young children, adolescents, or adults. The compounds can be administered in utero. The compounds can be administered immediately after birth.
[0315] The compounds described herein can be administered orally, for example, with an inert diluent or with an absorbable edible carrier, or can be encapsulated in a hard or soft shell gelatin capsule, or can be compressed into tablets, or can be directly incorporated into the food of the diet. For oral therapeutic administration, the compounds described herein can be incorporated with excipients and used in the form of ingestible tablets, lozenges, troches, capsules, elixirs, suspensions, syrups and flakes. The compounds described herein can also be administered parenterally. Solutions of the compounds described herein can be prepared in water appropriately mixed with a surfactant such as hydroxypropylcellulose. Dispersants can also be prepared in glycerol, liquid polyethylene glycol, DMSO and mixtures thereof with or without alcohol, and in oils. Under normal storage and use conditions, these preparations can contain preservatives to prevent the growth of microorganisms. Conventional procedures and ingredients for selecting and preparing appropriate formulations are described in, for example, Remington's Pharmaceutical Sciences (2012, 22nd edition) and The United States Pharmacopeia: The National Formulary (USP 41NF 36), published in 2018. Pharmaceutical forms suitable for use as injections include sterile aqueous solutions or dispersions and sterile powders for extemporaneous preparation of sterile injection solutions or dispersions. In all cases, the form must be sterile and must be liquid to the extent that it can be easily administered by syringe. Compositions for nasal administration can be conveniently formulated into aerosols, drops, gels and powders. Aerosol formulations typically include solutions or fine suspensions of active substances in physiologically acceptable aqueous or non-aqueous solvents, and are typically presented in a single dose or multiple doses in a sterile form in a sealed container, which can be in the form of a cartridge or a refill for use with a nebulizer. Alternatively, the sealed container can be a single dispensing device, such as a single dose nasal inhaler or an aerosol dispenser equipped with a metering valve, which is intended to be discarded after use. When the dosage form includes an aerosol dispenser, it will contain a propellant, which can be a compressed gas (such as compressed air) or an organic propellant (such as fluorochlorocarbons). Aerosol dosage forms can also take the form of a pump atomizer. Compositions suitable for buccal or sublingual administration include tablets, lozenges and buccal tablets (pastilles), wherein the active ingredient is prepared together with a carrier (such as sugar, gum arabic, tragacanth, gelatin and glycerol). Compositions for rectal administration are conveniently in the form of suppositories containing conventional suppository bases (such as cocoa butter).
[0316] As described herein, the compounds described herein can be administered to animals, such as humans, alone or in combination with a pharmaceutically acceptable carrier in proportions determined by the solubility and chemical properties of the compound, the chosen route of administration, and standard pharmaceutical practice.
[0317] dose
[0318] The dosage of the compositions described herein (e.g., compositions comprising oligonucleotides) can vary according to many factors, such as the pharmacodynamic properties of the compound, the mode of administration, the age, health status and weight of the recipient, the nature and extent of the symptoms, the frequency of treatment, the type of concurrent treatment (if any), and the clearance rate of the compound in the animal to be treated. The compositions described herein can be initially administered at a suitable dose, which can be adjusted as needed, depending on the clinical response. In some embodiments, the dosage of the composition (e.g., a composition comprising an oligonucleotide) is a prophylactic effective amount or a therapeutically effective amount.
[0319] Reagent test kit
[0320] The present invention also particularly relates to a kit comprising (a) a pharmaceutical composition comprising an oligonucleotide reagent that reduces the level and / or activity of PCDH19 in a cell or subject as described herein, and (b) a package insert having instructions for performing any of the methods described herein. In some embodiments, the kit comprises (a) a pharmaceutical composition comprising an oligonucleotide reagent that reduces the level and / or activity of PCDH19 in a cell or subject as described herein, (b) an additional therapeutic agent, and (c) a package insert having instructions for performing any of the methods described herein.
[0321] How to choose ASO
[0322] Bioinformatics methods can be used to select oligonucleotides suitable for ASO treatment. The length of the oligonucleotide can be 15-30 (e.g., 18-22, such as 19, 20 or 21) nucleotides. The GC content of the oligonucleotide can be from about 40% to about 70% (e.g., 45%, 50%, 55%, 60%, 65% or 70%). The oligonucleotide can contain 3 or less (e.g., 2, 1 or 0) mismatches with human PCDH19. The oligonucleotide can contain at least 80% (e.g., 85%, 90%, 95%, 97%, 99% and 100%) sequence identity with the isometric target of human PCDH19. The oligonucleotide can contain at least 3 (e.g., 4, 5, 6, 7, 8, 9, 10 or more) mismatches with non-PCDH19 transcripts. The oligonucleotide may not form a dimer. The oligonucleotide may not form a hairpin. The oligonucleotide may lack a poly-G run, such as GGGG.
[0323] ASO Evaluation
[0324] Various techniques known in the art can be used to evaluate and confirm the activity of the antisense oligonucleotides disclosed herein. For example, the ability of antisense oligonucleotides to inhibit PCDH19 expression can be evaluated in an in vitro assay to confirm that the antisense oligonucleotides are suitable for treating diseases or conditions associated with PCDH19 mutations. Mouse models can be used not only to evaluate the ability of antisense oligonucleotides to inhibit PCDH19 expression, but also to improve symptoms associated with PCDH19 mutations.
[0325] In one example, cells (such as mammalian cells, such as CHO cells) transfected with PCDH19 and expressing the gene are also transfected with antisense oligonucleotides disclosed herein. Typically, PCDH19 contains mutations, such as missense, nonsense or frameshift (e.g., insertion or deletion) mutations. In another example, a human neuronal cell line (e.g., SH-SY5Y) that naturally expresses natural wild-type PCDH19 is used. Optionally, the genome of the cell is edited to contain mutations so that PCDH19 is a pathogenic variant. As is well known in the art, qRT-PCR or Northern blotting can be used to assess the level of PCDH19 mRNA. The level of protein expressed by PCDH19 can be assessed by Western blotting of total cell lysates or fractions, as described by Rizzo et al. (Mol Cell Neurosci. 72: 54-63, 2016).
[0326] In a specific example, the activity of the antisense oligonucleotides disclosed herein is evaluated and confirmed using a stem cell model (for review, see, e.g., Tidball and Parent Stem Cells 34: 27-33, 2016; Parent and Anderson Nature Neuroscience 18: 360-366, 2015). For example, human induced pluripotent stem cells (iPSCs) can be generated from somatic cells (e.g., dermal fibroblasts or blood-derived hematopoietic cells) derived from patients with PCDH19 mutations and presenting related diseases or conditions (e.g., EIEE9). Optionally, genome editing can be used to revert mutations to wild type to produce isogenic control cell lines (Gaj et al. Trends Biotechnol 31, 397-405, 2013), which can also be used to determine the desired wild-type activity level for subsequent evaluation and comparison of oligonucleotides. Alternatively, genome editing can be used to introduce mutations into the PCDH19 gene of a wild-type control iPSC (e.g., a reference iPSC line). Then, iPSCs containing mutations (optionally, and isogenic controls) can be differentiated into neurons, including excitatory neurons, using known techniques (see, e.g., Kim et al. Front Cell Neurosci 8: 109, 2014; Zhang et al. 2013, Chambers et al. Nat Biotechnol 27, 275-280, 2009). After iPSCs are exposed to the antisense oligonucleotides of the invention, the effects of the antisense oligonucleotides of the invention on PCDH19 expression (e.g., as assessed by PCDH19 mRNA or protein levels) and / or activity (e.g., as assessed by calcium binding) can be assessed.
[0327] The PCDH19 expression level (mRNA or protein) observed when the cells expressing PCDH19 are exposed to the antisense oligonucleotides of the present invention is compared with the corresponding level observed when the cells expressing PCDH19 are exposed to the negative control antisense oligonucleotides to determine the inhibition level produced by the antisense oligonucleotides of the present invention. Typically, the expression level of PCDH19 is reduced by at least or about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or more. Therefore, the antisense oligonucleotides of the present invention can be used to treat diseases or disorders associated with PCDH19 mutations.
[0328] The functional effects of administering antisense oligonucleotides can also be evaluated by using mixing experiments, such as those described in Pederick et al. Neuron 97: 59-66, 2018 (which is hereby incorporated by reference in its entirety). K562 cells can be used because they do not aggregate during culture due to the lack of endogenous PCDH and classical cadherin. These cells can be engineered to express a combination of PCDH19 (WT or mutant) with another non-clustering PCDH (such as PCDH17 and / or PCDH10). In some specific examples, cells can express both WT and mutant PCDH19. Two populations of fluorescently labeled K562 cells expressing the same or different PCDH combinations can be mixed in a 1: 1 ratio. The contribution of each population in the resulting cell aggregates can be evaluated. Aggregates dominated by one population can indicate cell sorting due to different adhesion specificities, while heterogeneous aggregates can indicate cell mixing due to the same adhesion specificity. If the pathogenic variant results in sorting rather than mixing, cells containing the PCDH19 mutant can be treated with an ASO (e.g., an allele-specific ASO) and the results of the cell sorting experiment can be reassessed. If subsequent results indicate mixing rather than sorting, the ASO can be considered to have successfully targeted and reduced expression of the mutant PCDH19.
[0329] Mouse models can also be used to evaluate and confirm the activity of the antisense oligonucleotides disclosed herein. For example, a knock-in or transgenic mouse model can be generated using a PCDH19 gene containing a mutation, in a manner similar to the previously described SCN1A and SCN2A knock-in and transgenic mouse models (see, e.g., Kearney et al. Neuroscience 102, 307-317, 2001; Ogiwara et al. J Neurosci 27: 5903-5914, 2007; Yu et al. Nat Neurosci 9: 1142-1149, 2006). In a specific example, a PCDH19 gene matched with a specific antisense oligonucleotide is used to generate a knock-in or transgenic mouse. Mutant PCDH19 knock-in or transgenic mice can present a phenotype similar to EIEE9, including, e.g., increased neuronal activity, spontaneous epileptic seizures, and heterogeneous focal epileptic seizure activity on an electroencephalogram (EEG). The antisense oligonucleotides of the invention can then be evaluated for their ability to inhibit PCDH19 expression and ameliorate any symptoms associated with PCDH19 mutations in these mice.
[0330] In another example, the level of PCDH19 mRNA and / or protein can be assessed after the antisense oligonucleotides of the present invention or negative control antisense oligonucleotides are applied to mice. In a specific example, PCDH19 mRNA and / or protein levels in the brain (particularly neurons) are assessed. The expression level of PCDH19 after the antisense oligonucleotides of the present invention are compared with the corresponding levels observed when the negative control antisense oligonucleotides are applied to determine the inhibition level produced by the antisense oligonucleotides of the present invention. Typically, the expression level of PCDH19 in mice (e.g., in the brain of mice) is reduced by at least or about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or more.
[0331] In another example, the functional effect of antisense oligonucleotides of the present disclosure is evaluated. For example, the number, severity and / or type of epileptic seizures can be evaluated by vision and / or electroencephalogram. Neuronal excitability can also be evaluated, such as by excising brain slices from mice using antisense oligonucleotides of the present disclosure or negative control antisense oligonucleotides, and evaluating whole-cell current (e.g., using whole-cell patch clamp techniques) to carry out. Similar neuronal excitability analysis can be carried out using neurons separated and then cultivated from mice. In addition, mouse behavior can be evaluated, including gait characteristics, to determine the functional effect of antisense oligonucleotides of the present disclosure.
[0332] All publications, patents, and patent applications mentioned in this specification are incorporated herein by reference in their entirety to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference in its entirety. When a term in this application is found to have a different definition in a document incorporated herein by reference, the definition provided herein will serve as the definition of the term.
[0333] Reference in this specification to any previous publication (or information derived therefrom) or any known matter is not, and should not be taken as, an acknowledgement or acknowledgment or any form of implication that the previous publication (or information derived therefrom) or known matter constitutes part of the common general knowledge in the field of work to which this specification relates.
[0334] Although the invention has been described in conjunction with specific embodiments thereof, it will be understood that the invention is capable of further modifications, and this application is intended to cover any variations, uses, or adaptations of the invention following generally the principles of the disclosure and including such departures from the invention as come within known or customary practice in the art to which the invention pertains and which may be applied to the basic features set forth above and which follow the scope of the claims.
[0335] Example
[0336] Example 1. ASO design and production
[0337] Exemplary 15-mer, 16-mer, 17-mer and 20-mer antisense oligonucleotides (ASOs) were generated for the human PCDH19 gene listed in the NCBI reference sequence: NC_000023.11 (SEQ ID NO: 1), which is located on the complementary strand within the region (100291644..100410273) (SEQ ID NO: 1). The 5' end of the ASO target site was assigned to the position within the gene as listed in Table 2 below. The nucleotide composition was determined, and ASOs with a GC content of <20% or >80% were excluded from further analysis. The cross-reactivity of the ASOs was calculated for all known PCDH19 mRNA and pre-mRNA transcripts from NCBI RefSeqDB and EnsemblDB to identify ASOs that target as many different protein-coding transcripts as possible. Off-target ASOs (with up to 2 mismatches) were excluded from further analysis. Single nucleotide polymorphisms (SNPs) located in the ASO target site were identified based on the human PCDH19 gene (NC_000023.11; region: complementary (100291644..100410273)), and ASOs targeting such sites that contained SNPs with a minor allele frequency of ≥1% were excluded from further analysis. The remaining ASOs were further screened based on cross-reactivity with non-human primates and dogs. From this analysis, 384 ASO candidates (SEQ ID NO: 2 to SEQ ID NO: 385) were selected for synthesis and in vitro screening, as shown in Table 2.
[0338] Example 2. Screening of ASOs by evaluating inhibitory activity against PCDH19
[0339] Exemplary ASOs (SEQ ID NOs: 2 to 385) as listed in Table 2 were screened using HEK293 cells (ATCC) seeded at a density of 30,000 cells per well in 96-well plates. Cells were transfected with 0.2 nM or 2.0 nM of each ASO using 0.4 μl of Lipofectamine 2000 transfection reagent (Invitrogen) per well. PCDH19 mRNA expression in cell lysates was quantified 48 h after transfection using the Quantigenesingleplex branched DNA assay (ThermoFisher). PCDH19 expression was normalized to GAPDH and is expressed as a combined average relative to mock-transfected cells and cells transfected with the Ahsa1 ASO that does not cross-react with PCDH19. Data calculated from four independent experiments are shown in Table 2 (as means and standard deviations) and Figure 1 middle.
[0340] Example 3. Treatment of EIEE9 by administration of ASO
[0341] A female patient with EIEE9 was selected for ASO treatment. A 16mer ASO targeting PCDH19 mRNA was synthesized, using phosphorothioate bonds as a whole and with 2MOE modifications on all sugar moieties. The ASO was dissolved in an appropriate excipient compatible with administration to humans. A solution containing the dissolved ASO was injected into the patient's brain so that the ASO solution interacted with the targeted neurons in the brain. The ASO transfected neurons and altered the translation of PCDH19 in the target cells, resulting in a reduction in PCDH19 protein. A quantitative assay was performed to measure the reduction in PCDH19 protein. The patient received extensive regular testing to measure the reduction in seizures and other EIEE9-related symptoms after administration of the ASO treatment.
[0342] Table 2. Inhibitory activity of antisense oligonucleotides
[0343]
[0344] 1 The specificity of the ASOs is human / nonhuman primate, except for ASO numbers 13, 109-112, 138-140, 155-164, 169-172, 176, 179-182, 209, 224, 280, 281, 310-317, 324, 341, and 384, which are specific for human / nonhuman primate / canine
[0345]
[0346]
[0347]
[0348]
[0349]
[0350]
[0351]
[0352]
[0353]
[0354]
[0355]
[0356]
[0357]
[0358]
[0359]
[0360]
Claims
1. A single-stranded oligonucleotide having a length of 10-80 nucleosides and a nucleobase sequence comprising a portion of 10 consecutive nucleobases having at least 80% complementarity with an equal length portion of a target region of a human PCDH19 gene, a pre-mRNA transcript thereof and / or an mRNA transcript thereof.
2. The oligonucleotide of claim 1, wherein the target region is within the nucleotide sequence of SEQ ID NO: 1 or a variant thereof having at least or about 80% sequence identity thereto.
3. The oligonucleotide according to claim 1 or 2, wherein the mRNA transcript or pre-mRNA transcript comprises at least one PCDH19 mutation.
4. The oligonucleotide of claim 3, wherein the at least one PCDH19 mutation is selected from mutations encoding N340S, E307K, V441E, Q85X, N557K, D594H, S671X, L677fsx717, I119fsX122 and P364fsX375, or is a mutation selected from Table 1.
5. The oligonucleotide according to claim 3 or 4, wherein the oligonucleotide selectively hybridizes to an mRNA transcript or pre-mRNA transcript comprising the at least one PCDH19 mutation, but not to a wild-type mRNA transcript or pre-mRNA transcript.
6. The oligonucleotide according to any one of claims 1 to 5, wherein the oligonucleotide consists of 12 to 40 nucleobases, 16 to 30 nucleobases or 18 to 22 nucleobases.
7. The oligonucleotide according to any one of claims 1 to 6, wherein the oligonucleotide comprises: (a) a gap segment comprising linked deoxyribonucleosides; (b) a 5' wing segment comprising linked nucleosides; and (c) a 3' wing segment comprising linked nucleosides; wherein the gap fragment comprises a region of at least 10 consecutive nucleobases, which has at least 80% complementarity with an equal length portion of a target region of a pre-mRNA transcript or an mRNA transcript of a human PCDH19 gene, and is located between the 5' wing fragment and the 3' wing fragment; wherein the 5' wing fragment and the 3' wing fragment each comprise at least two linked nucleosides; and wherein at least one nucleoside of each wing fragment comprises an alternative nucleoside.
8. The oligonucleotide according to any one of claims 1 to 7, wherein the oligonucleotide comprises at least one alternative internucleoside linkage, at least one alternative nucleobase and / or at least one alternative sugar moiety.
9. The oligonucleotide according to claim 8, wherein the at least one alternative internucleoside linkage is selected from a phosphorothioate internucleoside linkage, a 2'-alkoxy internucleoside linkage or an alkylphosphate internucleoside linkage.
10. The oligonucleotide of claim 8, wherein the alternative nucleobase is 5'-methylcytosine, pseudouridine or 5-methoxyuridine.
11. The oligonucleotide of claim 8, wherein the alternative sugar moiety is a 2'-OMe modified sugar moiety or a bicyclic sugar moiety.
12. The oligonucleotide according to any one of claims 1 to 11, wherein the oligonucleotide further comprises a ligand conjugated to the 5' end or the 3' end of the oligonucleotide via a monovalent or branched divalent or trivalent linker.
13. The oligonucleotide according to any one of claims 1 to 12, wherein the oligonucleotide comprises a region complementary to at least 17 or at least 19 consecutive nucleotides of the PCDH19 gene.
14. The oligonucleotide according to any one of claims 1 to 13, wherein the oligonucleotide comprises the sequence shown in any one of SEQ ID NOs: 2 to 385.
15. A pharmaceutical composition comprising the oligonucleotide according to any one of claims 1 to 14 and a pharmaceutically acceptable carrier or excipient.
16. The composition according to claim 15, comprising lipid nanoparticles, polymer nanoparticles, lipid complex nanoparticles or liposomes.
17. A method for treating, preventing or delaying the progression of a PCDH19-related disease in a subject in need thereof, or inhibiting the transcription of PCDH19 or reducing its level and / or activity in cells of a subject suffering from a PCDH19-related disease, the method comprising administering to the subject an oligonucleotide according to any one of claims 1 to 14 or a pharmaceutical composition according to claim 15 or 16 in an amount and for a duration sufficient to treat, prevent or delay the progression of a PCDH19-related disease, obtain degradation of mRNA transcripts of the PCDH19 gene, or reduce the level and / or activity of PCDH19 in cells.
18. The method of claim 17, wherein the cell is a cell of the central nervous system.
19. The method of claim 17 or 18, wherein the PCDH19-related disorder is selected from epilepsy, schizophrenia and autism.
20. The method of any one of claims 17 to 19, wherein the subject has a mutation in at least one allele of the PCDH19 gene.
21. The method of claim 20, wherein the oligonucleotide selectively reduces expression of an allele comprising a mutation relative to an allele not comprising a mutation, or wherein the oligonucleotide reduces expression of an allele comprising a mutation and an allele comprising a wild-type sequence.
22. The method of claim 20, wherein the mutation is a missense mutation, a nonsense mutation, or a frameshift mutation.
23. The method of any one of claims 17 to 22, wherein the method reduces one or more symptoms of a PCDH19-related disorder.
24. The method of claim 23, wherein the one or more symptoms of the PCDH19-related disorder are selected from the group consisting of long-term epileptic seizures, frequent epileptic seizures, behavioral and developmental delays, movement and balance problems, orthopedic conditions, language and speech delay problems, growth and nutrition problems, sleep difficulties, chronic infections, sensory integration disorders, autonomic nervous system disorders, and sweating.
